US Pat. No. 9,108,955

HETEROCYCLIC INHIBITORS OF NECROPTOSIS

President and Fellows of ...

1. The compound

US Pat. No. 9,235,887

CLASSIFICATION OF BIOLOGICAL TISSUE BY MULTI-MODE DATA REGISTRATION, SEGMENTATION AND CHARACTERIZATION

Elucid Bioimaging, Inc., ...

1. A method for classifying multiple voxels within dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) images
acquired over a series of time periods, the method comprising:
receiving a 2D or 3D image for each time period from among the corresponding set of DCE MRI images, the image representing
a plurality of voxels having a respective plurality of voxel locations, the plurality of voxels including multiple voxels
in a region of interest (ROI) being representative of the ROI in the corresponding time period;

determining 2D or 3D textural features for at least the multiple voxels in the ROI in each image at each time period in the
series of time periods;

determining kinetic texture features for each of the voxel locations in the ROI across all time periods in the series of time
periods to represent spatio-temporal changes in the textural features of each of the voxels in the ROI over the series of
time periods;

fitting a mathematical model to the determined kinetic texture features representing the changes in the textural features
of each of the voxel locations in the ROI;

determining parameter values of the mathematical model that is fitted to the changes in texture for each of the voxel locations
in the ROI by selecting individual unpaired coefficients from the mathematical model as the determined parameters;

applying a classifier to the determined kinetic texture features and to the determined parameters of the mathematical model
of changes in spatio-temporal texture to identify an abnormality in the ROI and to classify the abnormality into one of at
least two classes; and

visually indicating the classified abnormality as determined by the classifier for at least a portion of ROI in the image.

US Pat. No. 9,603,243

SILK ELECTRONIC COMPONENTS

TUFTS UNIVERSITY, Medfor...

1. A silk electronic component comprising:
a silk matrix; and
a plurality of conductive metamaterial elements that are coupled to the silk matrix,
wherein elements of the plurality of conductive metamaterial elements are arranged in an array to form at least one patterned
structure, and

wherein at least one dimension of the structure is smaller than a wavelength of incident electromagnetic radiation so that,
when the silk electronic component is exposed to the electromagnetic radiation, the radiation is modulated such that the silk
electronic component exhibits a subwavelength resonant electromagnetic response.

US Pat. No. 9,599,891

FABRICATION OF SILK FIBROIN PHOTONIC STRUCTURES BY NANOCONTACT IMPRINTING

TRUSTEES OF TUFTS COLLEGE...

1. A method of manufacturing a biophotonic nano-material, the method comprising steps of:
providing a substrate having a lithographically nanopatterned structure on a surface thereof;
providing an aqueous silk-fibroin solution;
depositing the solution on the lithographically nanopatterned surface of the substrate;
drying the solution to form a solidified silk-fibroin film haying a surface in contact with the nanopatterned surface of the
substrate, which film is characterized by beta-sheet secondary structure and by a nanopatterned imprint in the contacted surface
of the film transferred from the nanopatterned surface of the substrate; and

mechanically removing the film from the substrate,
wherein the film is characterized in that when it is exposed to photonic radiation it exhibits it spectral response corresponding
to the lithographically nanopatterned imprint, and

wherein the biophotonic nano-material is characterized such that when a biological material selected from the group consisting
of red blood cells, horseradish peroxidase, a nucleic acid, cells, an antibody, enzymes, peroxidase, lipase, amylose, organophosphate
dehydrogenase, ligases, restriction endonuclease, ribonucleases, DNA polymerases, glucose oxidase, laccase, viruses, proteins,
peptides, amino acids, DNA, RNA, RNAi, nucleotides, bacteriorhodopsin, and protorhodopsin is embedded in the film or coated
on its surface, one or both of its structure and its biological activity is not materially degraded, reduced, and/or inhibited.

US Pat. No. 9,539,231

METHOD FOR TREATING TRIPLE-NEGATIVE BREAST CANCER USING AMPI-109

The Regents of the Univer...

1. A method for treating triple-negative breast cancer, comprising:
administering a drug comprising AMPI-109 in an amount effective for treating or preventing triple-negative breast cancer to
a patient in need thereof, wherein AMPI-109 has a chemical structure of


US Pat. No. 9,056,899

ENGINEERED BACTERIOPHAGES AS ADJUVANTS FOR ANTIMICROBIAL AGENTS AND COMPOSITIONS AND METHODS OF USE THEREOF

Trustees of Boston Univer...

1. An engineered bacteriophage comprising a nucleic acid operatively linked to a promoter, wherein the nucleic acid encodes:
a bacterial porin or porin-like protein of the OMP superfamily.

US Pat. No. 9,557,423

DIRECTION SENSITIVE NEUTRON DETECTOR

Trustees of Boston Univer...

1. A neutron detector, comprising:
a pressure vessel having a pressurized gas mixture of CF4, 3He and 4He at respective partial pressures, a first partial pressure ratio of CF4 to 3He being substantially 1:1 or greater, and a second partial pressure ratio of 4He to CF4 being substantially 15:1 or greater, the pressure vessel having first and second opposite ends, the first end having an optically
transparent window;

an electrically conductive field cage assembly within the pressure vessel, the field cage assembly being configured and operative
to establish first and second electric field regions in the pressure vessel, the first electric field region being a relatively
large drift region of relatively low field strength in which ionization electrons generated by neutron-He interactions are
directed toward the second electric field region, the second electric field region being a substantially smaller region of
substantially higher field strength at the second end of the pressure vessel in which the ionization electrons undergo avalanche
multiplication resulting in scintillation of the CF4 along scintillation tracks; and

an imaging subsystem including (1) a camera at the optically transparent window of the first end of the pressure vessel, the
camera being operative in response to scintillation light from the amplification region to generate camera output signals
representative of a sequence of images captured by the camera, and (2) an image processor operative to process the camera
output signals in real time to (a) identify the scintillation tracks and (b) based on the identification of the scintillation
tracks, estimate a rate and direction of incident neutrons.

US Pat. No. 9,234,288

CONDUCTOR OF HIGH ELECTRICAL CURRENT AT HIGH TEMPERATURE IN OXYGEN AND LIQUID METAL ENVIRONMENT

Infinium, Inc., Natick, ...

1. An apparatus comprising:
(a) a tube having a first end and a second end, the tube comprising a material stable in an environment with oxygen partial
pressure above 0.1 atm and robust in thermal gradients of at least 10° C./cm;

(b) a first electronic conductor disposed at the first end of the tube; and
(c) a second electronic conductor for electrically connecting the first electronic conductor to the current source of an electrolytic
cell, the second conductor being at least partially disposed within the tube;

wherein the tube and the first conductor form a gas tight sheath between the second conductor and an oxygen environment outside
the tube.

US Pat. No. 10,004,800

ANTIBODY EVOLUTION IMMUNOGENS

Duke University, Durham,...

1. A composition comprising a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879 or SEQ ID NO: 861 and a carrier.
US Pat. No. 9,896,660

PRODUCTION OF RED BLOOD CELLS AND PLATELETS FROM STEM CELLS

BOSTON MEDICAL CENTER COR...

1. A method of making megakaryocyte-erythroid progenitor cells (MEPs), comprising:
providing MEP precursor cells; and
culturing the MEP precursor cells in the presence of an aryl hydrocarbon receptor (AhR) antagonist for a first culture period
of at least three hours and then culturing the resultant MEP precursor cells in the presence of an AHR agonist for a second
culture period to make MEPs.

US Pat. No. 9,903,820

CHEMICAL FUNCTIONALIZATION OF SOLID-STATE NANOPORES AND NANOPORE ARRAYS AND APPLICATIONS THEREOF

The Trustees of Boston Un...

1. A method for determining nucleotide sequences of polynucleotides, the method comprising the steps of:
providing an optically-addressable nanopore array comprising a solid-state insulating membrane having a plurality of nanopores,
wherein the optically-addressable nanopore array separates a cis chamber from a trans chamber and wherein the nanopores are
spaced so that fluorescence from adjacent nanopores is spatially resolved;

translocating fluorophore-labeled polynucleotides through the nanopores from the cis chamber to the trans chamber; and
optically probing the nanopore array wherein an optical sensor of a plurality of optical sensors selectively addresses each
nanopore in the array to detect fluorescent emission variations as a function of time at each nanopore in the array, and wherein
each of said fluorescent emission variations from every nucleotide as a function of time from a nanopore is indicative of
a nucleotide sequence of a polynucleotide translocating therethrough.

US Pat. No. 9,355,363

SYSTEMS AND METHODS FOR VIRTUAL PARALLEL COMPUTING USING MATRIX PRODUCT STATES

University of Central Flo...

23. A system for computing the probability of binary outputs of any algorithmically computable function given a probability
of binary inputs, comprising:
a storage unit being operative to store a plurality of input matrices and to store the algorithmically computable function
as interconnected gates, wherein the plurality of input matrices encode the weights of the binary inputs for the set of N
bits, each weight defined by a product of the input matrices, with each input matrix associated with a binary state for a
bit in the set of N bits, the input matrices describing a set of possible inputs for the algorithmically computable function
and the interconnected gates each represents a matrix operation, at least one of the gates performing a matrix operation on
at least one matrix that is input to the respective gate;

a matrix logic engine coupled to the storage unit and being operative to apply the interconnected gates to the plurality of
input matrices to obtain a plurality of output matrices that encode the weights of the binary outputs; and

a calculation unit being operative calculate a weight of a given output based at least in part on the plurality of output
matrices, the weight of the given output indicating a probability that the given output is generated by the algorithmically
computable function using the set of possible inputs.

US Pat. No. 9,199,250

DISPOSABLE SEPARATOR/CONCENTRATOR DEVICE AND METHOD OF USE

Trustees of Boston Univer...

1. A device for separation of particulates from a fluid sample by centrifugation, the device comprising:
a first chamber, the first chamber having an upper inlet for receiving the fluid sample to be processed by the device and
a lower outlet for discharging material;

a second chamber, the second chamber having an upper inlet for receiving a sample material from a first collection reservoir
in a first valve, and a lower outlet for discharging material;

a first channel connecting the lower outlet of the first chamber to the upper inlet of the second chamber;
the first valve disposed along the first channel, wherein the first valve forms a seal preventing material in the first chamber
from flowing in to the second chamber and wherein the first valve comprises the first collection reservoir for collecting
particulates from the first chamber,

a third chamber, the third chamber having an upper inlet for receiving a sample material from a second collection reservoir
in a second valve;

a second channel connecting the lower outlet of the second chamber to the upper inlet of the third chamber; and
the second valve disposed along the second channel wherein the second valve forms a seal preventing material in the second
chamber from flowing into the third chamber and wherein the second valve comprises the second collection reservoir for collecting
particulates from the second chamber.

US Pat. No. 9,376,714

METHOD FOR DETECTING AND QUANTIFYING RARE MUTATIONS/POLYMORPHISMS

Trustees of Boston Univer...

1. A method of detecting the presence of one or more nucleic acids with a rare mutation in a sample, wherein said rare mutation
includes any change from a wildtype sequence including polymorphisms that are present in less than 10% of the nucleic acid
molecules in the sample, comprising the steps of;
(a) providing a nucleic acid sample comprising a mixture of nucleic acids wherein the mixture of nucleic acids comprises at
least one nucleic acid with a rare mutation that is present in less than 10% of nucleic acids in the sample;

(b) in an amplification reaction amplifying the nucleic acid sample with primers flanking the sequence carrying the rare mutation,
wherein the primers allele-specifically amplify the nucleic acid with the rare mutation;

(c) removing excess dNTPs after the amplification reaction;
(d) performing a primer extension reaction using (i) one or more detection primers which are designed so that the 3? end of
the detection primer is immediately adjacent to a nucleic acid which differentiates the rare mutation carrying nucleic acid
from a wildtype nucleic acid molecule, and (ii) only one dNTP or only one ddNTP selected according to the rare mutation, wherein
the dNTP or the ddNTP corresponds to a nucleoside adjacent to the detection primer in the nucleic acids with the rare mutation;
and

(e) detecting the presence of the primer extension product(s) after the primer extension reaction and/or detecting the consumption
of the dNTP or the ddNTP,
wherein the presence of a primer extension product in the reaction or the consumption of the dNTP or the ddNTP indicates the
presence of the nucleic acid with a rare mutation.

US Pat. No. 9,495,542

SOFTWARE INSPECTION SYSTEM

Trustees of Boston Univer...

1. A method of scanning an item of executable binary code prepared from a program written in a programming language, the method
employing a model checker and executing on a host computer processor, the method comprising:
preparing a data structure corresponding to the item of executable binary code, the data structure comprising executable elements
parsed from the item of executable binary code;

creating a composite model of the executable binary code by supplementing the data structure with metadata comprising at least
security rules defined by a specification of the programming language and rules defining the format of instructions in the
programming language, the composite model having a format for processing by the model checker;

segmenting the composite model into a plurality of segments, segmenting comprising the steps of:
dividing the composite model into a plurality of initial, consecutive segments,
including at least a first segment; and
changing a distribution of instructions among the segments by, for each segment after the first segment, assessing at least
the first instruction in each segment, and moving the at least first instruction to an immediately preceding segment if that
at least first instruction is not a transfer instruction;

analyzing each of the plurality of segments individually, and analyzing boundaries of the segments, with the model checker
to assess whether the executable binary code violates a rule defined by the programming language; and

generating an output based on a result produced by the model checker, the output including an indication of whether the binary
code possibly contains malware.

US Pat. No. 9,174,988

SMALL MOLECULE INHIBITORS OF HEPATITIS C VIRUS

TRUSTEES OF BOSTON UNIVER...

1. A compound having the structure shown in formula (I):

wherein:
X is CR13 or N;

Y is O or S;
R11 is H, C(O)R17, CO2R17, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted, or R11 is a linker that links two compounds of formula (I) together;

R12 and R13 are independently for each occurrence H, halogen, N(R17)2, NO2, OR17, CF3, CN, C(O)R17, CO2R17, SO3R17, SR17, S(O)R17, S(O)2R17, CH(CO2R17)2, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl or heterocyclyl, each of which can be optionally substituted;

R14 is C(O)R17, CO2R17, C(O)N(R17)2, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted;

R15 is H, halogen, CF3, CN, —(CH2)tOR17 (t is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10), C(O)R17, CO2R17, OR17, SR17, S(O)R17, S(O)2R17, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cyclyl, heterocyclyl, each of which can be optionally substituted;

R16 is independently for each occurrence halogen, N(R17)2, NO2, OR17, CF3, CN, C(O)R17, CO2R17, SO3R17, SR17, S(O)R17, S(O)2R17, CH(CO2R17)2, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl or heterocyclyl, each of which can be optionally substituted;

R17 is independently for each occurrence H, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cyclyl, or heterocyclyl, each of
which can be optionally substituted

m is 1, 2, or 3;
n is 0, 1, 2, 3, or 4; and
stereoisomers and pharmaceutically acceptable salts thereof.

US Pat. No. 9,121,843

CHEMICAL FUNCTIONALIZATION OF SOLID-STATE NANOPORES AND NANOPORE ARRAYS AND APPLICATIONS THEREOF

Trustees of Boston Univer...

1. A device comprising:
a solid-state membrane, the membrane having a nanometer-scale thickness, the membrane having an aperture with at least one
surface that forms a nanopore open to two opposite sides of the membrane, wherein at least a portion of an analyte is capable
of passing through the nanopore,

wherein an organic chemical coating comprising a self-assembled monolayer is disposed inside the walls of the nanopore, and
wherein the organic chemical coating modifies at least one surface characteristic of the nanopore without specific binding
between the analyte and the nanopore wherein the at least one surface characteristic of the nanopore coating includes at least
one of concavity, surface charge, polarity, pH sensitivity, hydrophobicity, and functionality, to control the rate of passage
of the analyte through the nanopore.

US Pat. No. 9,457,047

IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF

Whitehead Institute, Cam...

1. A composition comprising ?-1-6-glucan linked to a targeting moiety, wherein the targeting moiety is selected from the group
consisting of an engineered binding protein, an antibody, an antibody fragment, a nucleic acid, a peptide, and a small molecule,
and wherein the targeting moiety specifically interacts with a neoplastic cell, a pre-neoplastic cell, a pathogen, or a component
thereof.
US Pat. No. 9,090,473

[N]CYCLOPARAPHENYLENES (CCP), [N]MACROCYCLE INTERMEDIATES AND METHODS OF MAKING SAME

TRUSTEES OF BOSTON UNIVER...

1. A composition comprising at least two molecules of cycloparaphenylene.
US Pat. No. 9,598,684

ROTHIA SPECIES GLUTEN-DEGRADING ENZYMES AND USES THEREOF

TRUSTEES OF BOSTON UNIVER...

1. A lyophilized probiotic composition comprising an effective amount of Rothia species bacteria and a pharmaceutically acceptable carrier, wherein the bacteria comprises a gluten-degrading enzyme that
retains protease activity at acidic pH of 3.0 as measured in an in vitro gliadin degradation assay for 3 hours using a synthetic
substrate Z-YPQ-pNA, wherein the enzyme, when purified, comprises an iso-electric point within a pH range of 2.0-7.0 inclusive,
and wherein the composition is formulated into granules.

US Pat. No. 9,433,336

SELF-CLEANING SOLAR PANELS AND CONCENTRATORS WITH TRANSPARENT ELECTRODYNAMIC SCREENS

Trustees of Boston Univer...

1. A film assembly usable to self-remove particles of material deposited thereon, comprising:
a film of transparent material; and
a set of elongated conductive electrodes carried by the film, the electrodes being configured to be connected to a source
of electrical power and to generate an electric field across a surface of the film in response thereto, the electric field
being of sufficient strength to remove the particles from the surface of the film by electrodynamic action, the electrodes
being separated from adjacent portions of the film by a coating of a dielectric material having substantially higher dielectric
strength than a dielectric strength of the film to protect against dielectric breakdown during operation.

US Pat. No. 9,091,862

PARTITIONED APERTURE WAVEFRONT IMAGING METHOD AND SYSTEM

TRUSTEES OF BOSTON UNIVER...

1. A partitioned aperture wavefront imaging system comprising:
a partitioned aperture lens array positioned at an aperture plane of the imaging system between an entrance plane and a camera
plane; and

an entrance lens positioned at either the entrance plane or the aperture plane or a position between the entrance plane and
the aperture plane of the imaging system;

wherein the partitioned aperture lens array includes at least two off-axis lenses symmetrically distributed about an optical
axis, and at least two images of an object presented at the entrance plane are simultaneously produced at the camera plane
for determination of a tilt and amplitude of the wavefront based on detected object images.

US Pat. No. 10,085,988

AGLAROXIN C AND DERIVATIVES AS HCV ENTRY INHIBITORS

SRI International, Menlo...

1. A method to inhibit hepatitis C viral infection by administering to a subject a therapeutically effective dosage of a compound having a structure of compound 2:
US Pat. No. 9,920,374

DIAGNOSTIC FOR LUNG DISORDERS USING CLASS PREDICTION

Trustees of Boston Univer...

1. A method of processing a sample of airway epithelial cells from a subject who is asymptomatic for lung cancer, comprising:
(a) receiving a sample of airway epithelial cells from the subject who is asymptomatic for lung cancer; and
(b) measuring, by reverse-transcription polymerase chain reaction (RT-PCR) analysis, the expression level of gene transcripts
in the sample, wherein the gene transcripts measured comprise IL-8, FOS, and BACH2.

US Pat. No. 9,585,930

THERAPEUTIC AGENT FOR EMPHYSEMA AND COPD

Trustees of Boston Univer...

1. A method for treating chronic obstructive pulmonary disorder (COPD) or emphysema in a human subject in need of treatment
for emphysematous damage by administering to the human subject a pharmaceutical composition comprising a GHK tripeptide.
US Pat. No. 9,480,696

PROTON-MOTIVE FORCE STIMULATION TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS AGAINST PERSISTENT BACTERIA

TRUSTEES OF BOSTON UNIVER...

1. A method for treating a chronic or persisting bacterial infection, the method comprising administering to a subject having
or at risk for a chronic or persisting bacterial infection an effective amount of an aminoglycoside antibiotic and an effective
amount of at least one proton motive force (PMF) stimulating compound selected from fructose and pyruvate as an adjuvant.

US Pat. No. 10,018,817

ADAPTIVE OPTICS FOR IMAGING THROUGH HIGHLY SCATTERING MEDIA IN OIL RESERVOIR APPLICATIONS

ARAMCO SERVICES COMPANY, ...

1. A laser scanning multi-photon fluorescence microscope system for imaging dynamic and stationary particles, fluorescent molecules, and fluid interfaces in reservoir scattering media, the system comprising:a two/multi-photon laser for generating a laser beam;
a deformable mirror in an optical plane, which is conjugate to the pupil plane of an objective lens, with a segmented light modulator or a continuous mirror surface, for modifying a phase of coherent light of the laser beam focused on a sample;
two pairs of conjugate lenses with two galvanometric scanners in an optical conjugate plane with the deformable mirror;
a microscope objective with a back pupil where the deformable mirror can image the beam in order to focus the beam and collect a fluorescence signal;
an image processing device with a digitizer for digitizing the fluorescence signal, processing the collected fluorescence values and displaying the results with a stitched image; and
wherein a fluid flow is tracked using smaller image windows and faster scan rates than with stationary images.
US Pat. No. 9,074,186

PRODUCTION OF RED BLOOD CELLS AND PLATELETS FROM STEM CELLS

BOSTON MEDICAL CENTER COR...

1. A method of making a red blood cell (RBC), comprising:
differentiating a pluripotent stem cell into a myeloid-erythroid progenitor cell (MEP) in culture in the presence of an aryl
hydrocarbon receptor (AhR) agonist; and

culturing the MEP under conditions sufficient to make a RBC.

US Pat. No. 10,098,967

SELF-ASSEMBLY OF THERAPEUTIC AGENT-PEPTIDE NANOSTRUCTURES

Ohio State Innovation Fou...

1. A nanotube comprising a wall, wherein the wall comprises a plurality of conjugates of Formula II
where n is from 1 to 4,
each R1 and R2 are, independent of one another, H, OH, lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower carboxamido, cyano, hydrogen or deuterium, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthio, sulfonate, sulfonic acid, trisubstituted silyl, N3, SH, SCH3, C(O)CH3, CO2CH3, or CO2H, or together two R1 or R1 and R2 can form a fused cycloalkyl or cycloheteroalkyl;
L is C(O)—(CH2)m—C(O), where m is from 1 to 6;
AA is a protected or unprotected lysyl-lysyl or lysyl-phenylalanyl-lysyl-lysyl (SEQ ID NO:6); wherein L is bonded at a side chain of one of the lysyl residues of AA.

US Pat. No. 10,087,149

SELECTIVE HISTONE DEACETYLASE 8 INHIBITORS

TRUSTEES OF BOSTON UNIVER...

1. A compound of formula (I):
wherein:
R1 is optionally substituted linear or branched alkyl, optionally substituted linear or branched alkenyl, optionally substituted linear or branched alkynyl, optionally substituted cyclyl, optionally substituted heterocycicyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, CN, CF3, C(O)R5, CO2R5, C(O)N(R6)2, OR5, SR5, SOR5, SO2R5, SSR5 N(R6)2, NHR6, NR6C(O)R5, or NO2, each of which can be optionally substituted, wherein the backbone of alkyl, alkenyl, or alkynyl optionally comprises one or more heteroatoms, and wherein the carbon to which R1 is attached has the S stereochemistry;
R2 is optionally substituted linear or branched alkyl, optionally substituted linear or branched alkenyl, optionally substituted linear or branched alkynyl, optionally substituted cyclyl, optionally substituted heterocycicyl, optionally substituted aryl, optionally substituted heteroaryl, halogen, CN, CF3, C(O)R5, CO2R5, C(O)N(R6)2, OR5, SR5, SOR5, SO2R5, OSO2R5, SSR5, N(R6)2, NHR6, NR6C(O)R5, or NO2, each of which can be optionally substituted, and wherein the backbone of alkyl, alkenyl, or alkynyl optionally comprises one or more heteroatoms;
R3 is H, optionally substituted linear or branched alkyl, optionally substituted linear or branched alkenyl, optionally substituted linear or branched alkynyl, optionally substituted cyclyl, optionally substituted heterocycicyl, or optionally substituted aryl, optionally substituted heteroaryl;
R4 is —C(O)R7, —NH—P(O)OR5—R5, —SO2R5, —SO2N(R6)2, —SO2NR6OR5, or —SR5;
R5 is independently for each occurrence H, optionally substituted linear or branched alkyl, optionally substituted linear or branched alkenyl, optionally substituted linear or branched alkynyl, optionally substituted cyclyl, optionally substituted heterocyclcyl, optionally substituted aryl, optionally substituted heteroaryl, wherein the backbone of alkyl, alkenyl, or alkynyl optionally comprises one or more heteroatoms;
R6 is independently for each occurrence H, optionally substituted linear or branched alkyl, optionally substituted linear or branched alkenyl, optionally substituted linear or branched alkynyl, optionally substituted cyclyl, optionally substituted heterocyclcyl, optionally substituted aryl, optionally substituted heteroaryl, C(O)R5, CO2R5, or SO2R5, each of which can be optionally substituted, wherein the backbone of alkyl, alkenyl, or alkynyl optionally comprises one or more heteroatoms;
R7 is independently for each occurrence optionally substituted alkyl, wherein said alkyl does not include an heteroatom in the backbone, NR6OR5, amino, —C(O)N(R6)2, optionally substituted cyclyl, optionally substituted aryl; optionally substituted heteroaryl; optionally substituted alkylamino, where two substituents together with the nitrogen do not form a ring, optionally substituted arylamino, or optionally substituted heteroarylamino; and
a hydrate, salt, or solvate thereof.
US Pat. No. 9,617,325

TREATMENT OF IGE-MEDIATED DISEASE

Boston Medical Center Cor...

1. A compound of the formula X1—R0 (SEQ ID NO: 214), wherein R0 comprises SEQ ID NO: 4 and X1 comprises
TT QSLKQLEERA ARNVSQVSKN LESHHGDQMA QKSQSTQISQ ELEELRAEQQ RLKSQDLELS WNLNGLQADL SSFKSQELNE RNEASDLLER LREEVTKLRM ELQVS (SEQ
ID NO: 7), or a contiguous fragment of at least 15 amino acids of SEQ ID NO: 7, and wherein the compound comprises an amino
acid substitution D107E of SEQ ID NO: 4, or wherein the compound does not comprise amino acids 290-298 of SEQ ID NO: 3; or
wherein the compound does not comprise amino acids 290-321 of SEQ ID NO: 3.

US Pat. No. 9,599,611

STRUCTURED SUBSTRATES FOR OPTICAL SURFACE PROFILING

TRUSTEES OF BOSTON UNIVER...

1. A method for measuring target molecule binding to a microarray, said method comprising:
(i) providing a microarray comprising a plurality of spatially distinct binding locations, wherein each binding location comprises
substantially a single type of capture molecule bound to the surface of said microarray and each type of said capture molecules
specifically binds a type of target molecule;

(ii) contacting said microarray with a sample comprising one or more target molecules;
(iii) assessing the binding of said target molecules to said capture molecules by:
(a) sweeping a tunable light source through a tuning range to sequentially illuminate said microarray from above with light
comprising varying wavelengths and rays that are substantially perpendicular to the plane of said microarray;

(b) measuring the intensity of the light reflected from said microarray at each of said illuminating wavelengths using a photodetector
array;

(c) calculating the substrate reflectivity as a function of illuminating wavelength for each pixel of said photodetector array;
and

(d) comparing said calculated function to the function calculated prior to said contacting step (ii), wherein a difference
in said function at a pixel is an index of the binding of said target molecules to said capture molecules.

US Pat. No. 9,388,425

TUNABLE GENETIC SWITCH FOR REGULATING GENE EXPRESSION

TRUSTEES OF BOSTON UNIVER...

1. A method of dose-dependent gene expression of a heterologous target gene in a biological process in a cell, the method
comprising
(a) providing a cell with a heterologous target gene for expression, wherein the heterologous target gene is inserted into
the cell having a system comprising:

a nucleic acid sequence encoding an RNA interference molecule (RNAi) agent and a nucleic acid RNAi target sequence, wherein
the RNAi target sequence is not endogenous to the cell and is located within the 3?UTR or an intron sequence of the nucleic
acid sequence encoding the heterologous target gene,

wherein the RNAi molecule agent is substantially complementary to the RNAi target sequence such that gene silencing of the
RNAi target sequence and the heterologous target gene occurs in the presence of, and upon complementation with the RNAi molecule
agent;

wherein a nucleotide sequence encoding the heterologous target gene is operatively linked to a first repressor promoter sequence,
wherein the nucleotide sequence encoding the RNAi agent is operatively linked to a second repressor promoter sequence,
wherein the second repressor promoter sequence is controlled by a second repressor molecule,
wherein the nucleic acid sequence encoding the second repressor molecule is operatively linked to a second promoter and a
first repressor promoter sequence,

wherein the first repressor promoter sequence is controlled by a first repressor molecule,
wherein the nucleic acid sequence encoding the first repressor molecule is operatively linked to a first promoter,
wherein the first repressor molecule is inhibited by a small molecule inducer; and wherein the presence of the small molecule
inducer relieves repression of the first repressor promoter sequence thereby inducing the expression of the second repressor
molecule which represses the expression of the RNAi agent, thereby permitting dose-dependent gene expression of the heterologous
target gene; and

(b) contacting the cell with an effective amount of the small molecule inducer to induce the gene expression of the heterologous
target gene in a dose-dependent manner.

US Pat. No. 9,318,652

ULTRAVIOLET LIGHT EMITTING DIODE STRUCTURES AND METHODS OF MANUFACTURING THE SAME

Trustees of Boston Univer...

1. A light emitting diode device comprising:
a semiconductor substrate comprising a surface region;
a semiconductor structure overlying the surface region, the semiconductor structure comprising an active region of the light
emitting diode device, said active region being configured to emit electromagnetic radiation in an ultraviolet wavelength
range, the semiconductor structure comprising two quantum well layers, and at least one separation layer being configured
between the quantum well layers, the separation layer being configured to have a first mode to act as a barrier region for
separating a plurality of carriers in a quantum confined mode in each of the quantum well layers being provided on each side
of the separation layer; and a second mode configured to cause spreading of the plurality of carriers across each of the quantum
well layers to increase an overlap integral of the plurality of carriers from a first value to a second value, the second
value being greater than the first value, and the first value being associated with the first mode and the second value being
associated with the second mode;

wherein the second mode relates to a higher energy efficiency of the light emitting diode device than configured to operate
in the first mode when operating each mode in a same current density such that the second mode increases the overlap integral
of the plurality of carriers from the first value to the second value;

wherein the separation layer is tunable to an overlap of electron and hole wave functions over the active region.

US Pat. No. 9,155,792

RECA INHIBITORS WITH ANTIBIOTIC ACTIVITY, COMPOSITIONS AND METHODS OF USE

Trustees of Boston Univer...

1. A pharmaceutical composition comprising a RecA inhibitor, and at least one physiologically acceptable carrier or excipient,
wherein the composition further comprises at least one antibiotic and wherein the RecA inhibitor interacts directly with the
RecA protein and wherein the RecA inhibitor is selected from the group consisting of: amentoflavone, hinokiflavone, isorhamnetin,
maclurin, quercetagetin, quercetin dehydrate, 3,7,4?-trihydroxyflavone, theaflavin or a compound of formula (I) or formula
(II) or pharmaceutical acceptable salts thereof or combinations thereof, wherein the compound of formula (I) has the following
structure:

wherein:
X is oxygen, sulfur, or N(R);
n is 0 to 4;
R1 is hydrogen, or an optionally substituted group selected from a C1-6 aliphatic group, a monocyclic 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or a bicyclic 8-10 membered saturated, partially unsaturated, or aryl ring having
0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

each R2 is independently halogen, R3, OR3, SR3, N(R3)2, C(O)R3, C(O)OR3, NR3C(O)R3, C(O)NR3, SO2R3 NR3SO2R3 SO2N(R3)2;

each R3 is independently hydrogen or an optionally substituted group selected from a C1-6 aliphatic group, a monocyclic 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or a bicyclic 8-10 membered saturated, partially unsaturated, or aryl ring having
0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

Q is a valence bond or a bivalent, saturated or unsaturated, straight or branched C1-6 hydrocarbon chain, wherein 0-2 methylene units of Q are independently replaced by —O—, —NR—, —S—, —OC(O)—, —C(O)O—, —C(O)—,
—SO—, —SO2—, —NRSO2—, —SO2NR—, —NRC(O)—, —C(O)NR—, —OC(O)NR—, or —NRC(O)O—;

each R is independently hydrogen or an optionally substituted aliphatic group;
Rx is R or OR; and

Ring A is an optionally substituted 3-8 membered bivalent, saturated, partially unsaturated, or aryl monocyclic ring having
0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-10 membered bivalent
saturated, partially unsaturated, or aryl bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen,
or sulfur; and

wherein the compound of formula (II) has the following structure:

wherein:
Cy1 is a an optionally substituted 5-6 membered aryl ring having 0-3 heteroatoms independently selected from nitrogen, oxygen,
or sulfur;

L1 is a valence bond, a C1-6 bivalent saturated, unsaturated, straight or branched hydrocarbon chain, —N(R)—, —N(R)SO2—, —N(R)SO2N(R)—, —N(R)C(O)—, —C(O)N(R)—, or —N(R)C(O)N(R)—;

each R is independently hydrogen or an optionally substituted C1-6 aliphatic group;

Cy2 is an optionally substituted 6-membered aryl ring having 0-2 nitrogen atoms, an 8-10 membered bicyclic heteroaryl ring having
1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 5-membered heteroaryl
ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

L2 is a C1-6 bivalent saturated, unsaturated, straight or branched hydrocarbon chain, —CH2CH2C(?W)N(R)N(R)C(?W)—, —N(R)C(?W)N(R)C(?W)C(R)2W—, —C(?W)N(R)N(R)C(?W)N(R)—, —C(?W)N(R)N(R)C(?W)N(R)CH?CH2, or —C(?W)N(R)C(?W)N(R)—, wherein each W is independently oxygen or sulfur; and

Cy3 is an optionally substituted 6-membered aryl ring having 0-2 nitrogen atoms.

US Pat. No. 9,360,597

OPTICAL DEVICES WITH SPIRAL APERIODIC STRUCTURES FOR CIRCULARLY SYMMETRIC LIGHT SCATTERING

Trustees of Boston Univer...

1. An optical device operative in response to radiative electromagnetic energy to create a distribution of electromagnetic
energy having localized electromagnetic field enhancement, the optical device comprising a dielectric or plasmonic material
having a region of interaction with the radiative electromagnetic energy, the region of interaction having a deterministic,
aperiodic patterning with an array of individual patterning elements of distinct refractive indices such that a variation
of refractive index of the optical device occurs over distances comparable with or smaller than a wavelength of the incident
electromagnetic energy, the array having a spiral geometry imparting a substantially continuous and rotationally symmetric
characteristic to the distribution of electromagnetic energy created in response to the radiative electromagnetic energy.

US Pat. No. 9,284,562

BIOLOGICAL CIRCUIT CHEMOTACTIC CONVERTERS

Trustees of Boston Univer...

1. A biological circuit chemotactic converter composition comprising:
at least one input module (IM)n nucleic acid comprising an inducible promoter nucleic acid sequence (iPA) operably linked to a repressor nucleic acid sequence encoding a repressor protein (RA);

at least one genetic toggle switch (TS) n nucleic acid comprising a first repressible promoter nucleic acid sequence (rP1) that drives expression of a second repressor nucleic acid sequence (R2) encoding a second repressor protein, and a second repressible promoter nucleic acid sequence (rP2) that drives expression of a first repressor nucleic acid sequence (R1) encoding a first repressor protein, (rP1-R2 and rP2-R1), wherein the rP1 is inhibited by the first repressor protein and the rP2 is inhibited by the second repressor protein and wherein RA of at least one input module acts as a repressor for rP1 of at least one genetic toggle switch;

at least one logic module (LM)n nucleic acid consisting essentially of a repressible promoter nucleic acid sequence (rPB) operably linked to a repressor nucleic acid sequence (RB), wherein rPB is inhibited by the second repressor protein of at least one genetic toggle switch; and

at least two sensor module (SMA and SMB)n+1 nucleic acids, wherein each of the two sensor module nucleic acids comprises a repressible promoter nucleic acid sequence
(rPC and rPD, respectively) operably linked to a nucleic acid sequence encoding a sensor molecule (sensor A and sensor B) and wherein
n ?1; wherein the repressible promoter nucleic acid sequence of at least one sensor module is repressed by the repressor protein
encoded by at least one logic module, and the repressible promoter nucleic acid sequence of another of the at least two sensor
modules is directly repressed by the second repressor protein encoded by at least one genetic toggle switch; and wherein if
no input signal is received by the at least one input module nucleic acids, only sensor A is expressed, and wherein if an
input signal is received by at least one input module nucleic acid, then sensor A is not expressed; and

wherein the repressor proteins encoded by any of the logic module nucleic acid sequences are different from the repressor
proteins encoded by any of the at least one input module nucleic acid sequences and are different from the repressor proteins
encoded by any of the at least one genetic toggle switch nucleic acid sequences.

US Pat. No. 9,597,325

INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS

Trustees of Boston Univer...

1. A method of inhibiting LSF in a subject, the method comprising administering to the subject an effective amount of a compound
of formula (III), wherein the formula (III) has the structure:

wherein:
R1 is aryl, wherein the aryl can be optionally substituted with C1-C6 alkoxyl at ortho-position;

R2 and R3 are hydrogen or R2 and R3 together form a second bond between the carbons to which they are attached;

R4 is hydrogen;

R5 is selected from the group of hydrogen and C1-C6 alkyl;

R6 and R7 are hydrogen;

R10 and R11 are hydrogen;

or enantiomers, prodrugs, derivatives, and pharmaceutically acceptable salts thereof.

US Pat. No. 9,203,209

HIGH-POWER FIBER LASER EMPLOYING NONLINEAR WAVE MIXING WITH HIGHER-ORDER MODES

Trustees of Boston Univer...

1. A fiber laser, comprising:
a higher-order-mode (HOM) fiber, the HOM fiber supporting a plurality of guided modes of propagation including higher-order
modes, the HOM fiber having a predetermined mode-dependent dispersion characteristic defining a zero-dispersion wavelength
for a first higher-order mode, the zero-dispersion wavelength defining a set of respective higher-order modes, wavelengths
and phases of constituent optical signals of a predetermined pattern of nonlinear wave mixing in which at least one of the
constituent optical signals propagates in the first higher-order mode,

an optical signal source having an output coupled to an input point of the HOM fiber and operative to launch a first optical
signal into the HOM fiber, the first optical signal being a first one of the constituent optical signals and producing the
predetermined pattern of nonlinear wave mixing in the HOM fiber; and

an output optical element coupled to an output point of the HOM fiber, the output optical element operative to extract a second
optical signal from the HOM fiber, the second optical signal being a second one of the constituent optical signals and produced
by the pattern of nonlinear wave mixing, the second optical signal propagating in a second higher-order mode of the set of
modes defined by the zero-dispersion wavelength.

US Pat. No. 9,627,580

HIGH EFFICIENCY ULTRAVIOLET LIGHT EMITTING DIODE WITH BAND STRUCTURE POTENTIAL FLUCTUATIONS

Trustees of Boston Univer...

1. A method for manufacturing a device, the method comprising:
providing a substrate comprising a surface region into a process chamber;
forming an n-type material overlying the substrate;
forming an active region overlying the n-type region, wherein forming the active region comprises:
forming a metal layer comprising gallium on a growth surface;
forming the active region at a substrate temperature between 680° C. and 750° C.; and
providing a quantity of aluminum, a quantity of gallium, and a quantity of active nitrogen in the process chamber, wherein
a ratio defined by (the quantity of gallium)/(the quantity of active nitrogen?the quantity of aluminum) is between 1.1 and
10;

preventing formation of gallium droplets by interrupting growth of the active region until the growth surface is free of the
metal layer; and

forming a p-type material overlying the active region;
whereupon the optical device is characterized by an electromagnetic emission ranging from about 200 to 365 nm; and
wherein the active region has a macroscopic AlN mole fraction, and microscopic regions of reduced AlN mole fraction as compared
to the macroscopic AlN mole fraction; and

the active region is characterized by non-faceted growth.
US Pat. No. 10,801,038

OPTO-GENETIC MODULATOR

TRUSTEES OF BOSTON UNIVER...

1. A system comprising:a. a control module comprising a nucleic acid sequence encoding a chimeric photosensitive transcription factor operably linked to a promoter, wherein the photosensitive transcription fact comprises:
i. a transcription activation domain;
ii. a sequence-specific DNA binding domain; and
iii. a photo-sensitive actuator domain which is activated by photoirradiation in a defined range of wavelengths; and
b. a physiologically responsive module comprising a nucleic acid sequence encoding a gene of interest operably linked to an inducible promoter comprising:
i. a sequence element that binds the sequence-specific DNA binding domain of the photosensitive transcription factor, and
ii. a physiological response element comprising a binding site for a downstream responsive element antagonist modulator (DREAM) repressor, the binding of which is directly regulated by intranuclear calcium;
wherein expression of the gene of interest in a cell comprising the system requires the presence of both: (i) intranuclear calcium and (ii) photoirradiation within 400-900 nm.

US Pat. No. 9,230,818

PLANARIZATION OF GAN BY PHOTORESIST TECHNIQUE USING AN INDUCTIVELY COUPLED PLASMA

TRUSTEES OF BOSTON UNIVER...

1. A substrate comprising:
a first layer, the first layer having roughness features deviating from a surface plane; and
a sacrificial layer covering the roughness features, the sacrificial layer having an essentially planar surface,
wherein the first layer responds to a first etching method at a first etch rate,
the sacrificial layer responds to the first etching method at a second etch rate, and
the ratio of the second etch rate to the first etch rate is in the range of 0.2 to 1.2.
US Pat. No. 9,919,009

PRODUCTION OF RED BLOOD CELLS AND PLATELETS FROM STEM CELLS

BOSTON MEDICAL CENTER COR...

1. A method of making red blood cells (RBCs), comprising:
providing a first culture comprising myeloid-erythroid progenitor cells (MEPs) differentiated from pluripotent stem cells
in culture in the presence of an aryl hydrocarbon receptor (AhR) agonist; and

culturing the MEPs in erythroid specification media and in the presence of an AhR agonist to provide a second culture comprising
RBCs.

US Pat. No. 9,718,858

TUNABLE CONTROL OF PROTEIN DEGRADATION IN SYNTHETIC AND ENDOGENOUS BACTERIAL SYSTEMS

TRUSTEES OF BOSTON UNIVER...

1. A composition comprising:
a modified Mesoplasma florum ssrA protein degradation tag or a polynucleotide construct encoding the same;

wherein the modified degradation tag is degraded by Mesoplasma florum Lon protease at a higher rate compared to the unmodified Mesoplasma florum ssrA degradation tag,

wherein the modified protein degradation tag is not degraded by ClpXP, an E. coli Lon protease, or an Lactococcus lactis protease, and

wherein the modified protein degradation tag comprises one or more substitutions of amino acid residues corresponding to amino
acids 24-27 of SEQ ID NO: 1.

US Pat. No. 9,616,234

SYSTEM AND METHOD FOR NEURO-STIMULATION

Trustees of Boston Univer...

1. A method, comprising:
generating at least one bias signal using a system for providing sub-threshold stimulation, the system comprising an application
body with a stimulating element generating the at least one bias signal;

inputting the at least one bias signal to at least one sensory cell area of a chest region of a subject while the subject
is undergoing lung function, such that the sub-threshold stimulation is transferred to intercostal muscles of the subject;
and

inducing a neuroplastic response in the nervous system of the subject by inputting the at least one bias signal for at least
a period of time whereby the subject's lung function is improved by increasing an expansion or a contraction of lungs of the
subject during the subject's lung function.

US Pat. No. 9,611,501

METHOD AND DEVICE FOR RAPID DETECTION OF BACTERIAL ANTIBIOTIC RESISTANCE/SUSCEPTIBILITY

Trustees of Boston Univer...

1. A method for determining sensitivity of bacteria to an antibiotic, the method comprising: (a) immobilizing the bacteria
from a bacterial suspension by covalent attachment to a solid support prior to exposing the bacterial suspension to a combination
of a stressor and the antibiotic, (b) contacting said immobilized bacteria with an agent comprising a reporter moiety, which
preferentially binds to damaged bacterial cells, (c) subjecting said immobilized bacteria to the stressor in the presence
of the antibiotic without a bacterial growth phase subsequent to immobilization, (d) detecting a signal from said reporter
moiety in said immobilized bacteria after contacting said covalently immobilized bacteria with the stressor in the presence
of the antibiotic and without the need for bacterial growth phase subsequent to immobilization, and (e) comparing the signal
on the solid support from said immobilized bacteria in the presence of the antibiotic to a control comprising immobilized
bacteria subjected to the stressor in the absence of the antibiotic, wherein detection of an increase in said signal in the
presence of an antibiotic compared to a control indicates that said bacteria are susceptible to said antibiotic, and wherein
a signal that is comparable to the control in the presence of an antibiotic indicates that said bacteria are resistant to
said antibiotic.
US Pat. No. 9,534,224

CIS/TRANS RIBOREGULATORS

Trustees of Boston Univer...

1. A recombinant prokaryotic cell comprising, a first exogenous mRNA nucleic acid sequence and a second exogenous mRNA nucleic
acid sequence encoding a trans-activating RNA, wherein:
a. the first exogenous mRNA nucleic acid sequence comprises a ribosome binding site (RBS) upstream of a nucleic acid sequence
encoding a gene to be expressed, and a cis-repressive nucleic acid sequence located 5? of the RBS,

wherein the cis-repressive nucleic acid sequence comprises at least 4 nucleic acids that are complementary to, or substantially
complementary to at least 4 nucleic acids in the RBS and can, upon complementary base pairing of the at least 4 nucleic acids
of the cis-repressive nucleic acid sequence with the at least 4 nucleic acids in the RBS form a duplex that is part of a repressive
stem-loop structure, wherein the loop of the stem-loop structure is between 4-10 nucleotides; and

b. the second exogenous nucleic acid sequence comprises an inducible promoter operatively linked to a nucleic acid sequence
encoding the trans-activating RNA, wherein the trans-activating RNA comprises (i) a 5? non-stem nucleic acid sequence, comprising
at least 4 nucleotides that are complementary to, or substantially complementary to at least 4 nucleotides of the cis-responsive
nucleic acid sequence, and (ii) a stem-loop structure comprising a RNA duplex and loop;
wherein:
when the trans-activating RNA is not present, the cis-repressive nucleic acid sequence and RBS form the repressive stem-loop
structure, wherein the repressive stem-loop structure blocks access of a ribosome to the RBS thereby repressing the translation
of the gene, and

when the trans-activating RNA is present, the 5? non-stem nucleic acid sequence of the trans-activating RNA forms a duplex
with at least 4 nucleotides of the cis-repressive nucleic acid sequence, wherein the duplex disrupts the repressive stem-loop
structure to expose the RBS, thereby allowing translation of the gene.

US Pat. No. 9,664,400

AUTOMATED TECHNIQUE OF MEASURING ROOM AIR CHANGE RATES IN HVAC SYSTEM

Trustees of Boston Univer...

1. A method for estimating an air change rate of a room of a building using heating, ventilation and air conditioning (HVAC)
equipment supplying conditioned air to the room, comprising:
monitoring temperature of the room;
making one or more changes to air flow rate and/or supply temperature of the conditioned air supplied to the room; and
determining an air change rate of the room using a response of the temperature of the room to the one or more changes,
wherein determining the air change rate includes performing a model-based mathematical calculation including one or more first-order
differential equations for a relationship between a time rate of change of room air temperature and the air change rate,

and wherein the model-based mathematical calculation includes a contribution to the time rate of change of room air temperature
from a wall temperature of one or more of walls, ceiling and floor of the room.

US Pat. No. 9,175,001

[1,3] DIOXOLO [4,5-G] [1,2,4] TRIAZOLO [1,5-A] QUINOLINE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER

TRUSTEES OF BOSTON UNIVER...

1. A compound of structural formula XIV, XV or XVI;
or a pharmaceutically acceptable salt thereof wherein,
each X is independently O or S;
R1 is hydrogen or an alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;

R2 is hydrogen or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;

each R3 and each R6 is: (i) independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl,
aryl, heteroaryl or arylalkyl group; or (ii) the two R6 moieties and/or the two R3 moieties taken together with an alkylene, alkenylene or alkynylene group form a substituted or unsubstituted C3 to C6 ring;
and

R4, R5, R7, R8, R9, R10 R11 and R12 are each independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl,
aryl, heteroaryl or arylalkyl group.

US Pat. No. 10,208,312

CIS/TRANS RIBOREGULATORS

TRUSTEES OF BOSTON UNIVER...

1. A recombinant eukaryotic cell comprising, a first exogenous mRNA nucleic acid sequence and a second exogenous mRNA nucleic acid sequence encoding a trans-activating RNA, wherein:a. the first exogenous mRNA nucleic acid sequence comprises a internal ribosome entry site (IRES) upstream of a start codon and nucleic acid sequence encoding a gene to be expressed, and a cis-repressive nucleic acid sequence located within a 5? UTR upstream of the start codon,
wherein the cis-repressive nucleic acid sequence comprises at least 4 nucleic acids that are complementary to, or substantially complementary to at least 4 nucleic acids in the 5?UTR and can, upon complementary base pairing of the at least 4 nucleic acids of the cis-repressive nucleic acid sequence with the at least 4 nucleic acids in the 5?UTR form a duplex that is part of a repressive stem-loop structure, wherein the loop of the stem-loop structure is between 4-10 nucleotides; and
b. the second exogenous nucleic acid sequence comprises an inducible promoter operatively linked to a nucleic acid sequence encoding the trans-activating RNA, wherein the trans-activating RNA comprises (i) a 5? non-stem nucleic acid sequence, comprising at least 4 nucleotides that are complementary to, or substantially complementary to at least 4 nucleotides of the cis-responsive nucleic acid sequence, and (ii) a stem-loop structure comprising a RNA duplex and loop; wherein:
when the trans-activating RNA is not present, the cis-repressive nucleic acid sequence and 5?UTR form the repressive stem-loop structure, wherein the repressive stem-loop structure blocks access of a ribosome to the IRES thereby repressing the translation of the gene, and
when the trans-activating RNA is present, the 5? non-stem nucleic acid sequence of the trans-activating RNA forms a duplex with at least 4 nucleotides of the cis-repressive nucleic acid sequence, wherein the duplex disrupts the repressive stem-loop structure to expose the IRES, thereby allowing translation of the gene.
US Pat. No. 9,913,862

METHODS OF TREATING GRAM-NEGATIVE MICROBIAL INFECTIONS

Trustees of Boston Univer...

16. A pharmaceutical composition for treatment of a microbial infection comprising daptomycin in an amount that is not effective
by itself to treat the microbial infection, and a potentiating amount of a silver-containing compound, with a pharmaceutically
acceptable carrier, wherein the potentiating amount of the silver-containing compound is sufficient to expand the spectrum
of daptomycin, but is below a threshold level required to effectively treat the microbial infection when used alone.

US Pat. No. 9,833,570

BLOOD GLUCOSE CONTROL SYSTEM

Trustees of Boston Univer...

1. A sensor-driven glucose control system, comprising:
a glucose sensor operative to continually measure glucose level of a subject and generate a corresponding glucose level signal;
an insulin delivery device operative in response to an insulin dose control signal to infuse insulin into the subject; and
a controller operative to generate the insulin dose control signal in response to the glucose level signal by:
(1) modulating an instantaneous basal infusion rate of insulin about a nominal basal infusion rate in response to short-term
variations of the glucose level occurring over a short term on the order of seconds to minutes, and generating the insulin
dose control signal according to the modulated instantaneous basal infusion rate to deliver basal insulin determined by the
insulin dose control signal; and

(2) continually and autonomously adjusting the nominal basal infusion rate based on calculating a mathematical relationship
between the modulated instantaneous basal infusion rate and the nominal basal infusion rate over a longer term than the short
term, the adjusting autonomously influencing the modulated instantaneous basal infusion rate over the longer term to cause
the basal insulin to be responsive to physiological variations in the subject's basal metabolic insulin requirement over the
longer term.

US Pat. No. 9,993,577

DISSOLVABLE HYDROGEL COMPOSITIONS FOR WOUND MANAGEMENT AND METHODS OF USE

Trustees of Boston Univer...

1. A dissolvable hydrogel composition comprising: an adhesive hydrogel layer comprising(a) a first water-soluble crosslinkable polymer and
(b) a second water-soluble linear, branched, and/or dendritic crosslinkable polymer;
wherein the first and second cross-linkable polymers are linked by thioester linkages, wherein the first crosslinkable polymer comprises at least two thiol moieties and the second crosslinkable polymer comprises at least two cross-linking moieties that are capable of reacting with said at least two thiol moieties of the first crosslinkable polymer to form the thioester linkages between the first crosslinkable polymer and the second crosslinkable polymer, and wherein the first crosslinkable polymer has a chemical structure selected from the group consisting of structure (i) to structure (xii) shown as follows:
and any combination thereof, and wherein:each Q is independently selected from the group consisting of O, S, Se, NH, CH2, and any combination thereof;
each R is independently selected from the group consisting of hydrogen, straight or branched chain alkyl, cycloalkyl, aryl, olefin or alkene, alkyne, silyl, alkylsilyl, arylsilyl, alkylaryl or arylalkyl chain of 1-50 carbons, fluorocarbon, and any combinations thereof, wherein each alkyl, cycloalkyl, aryl, olefin, alkyne, silyl, alkylsilyl, arylsilyl, alkylaryl, fluorocarbon, or arylalkyl chain is optionally substituted internally or terminally by one or more hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or di-substituted amino, thiol thioester, sulfate, phosphate, phosphonate, halogen, poly(ethylene glycol), poly(ethylene oxide), poly(hydroxyacid), a carbohydrate, a protein, a polypeptide, an amino acid, a nucleic acid, a nucleotide, a polynucleotide, a DNA segment, a RNA segment, a lipid, a polysaccharide, an antibody, a pharmaceutical agent, an epitope for a biological receptor; and any combinations thereof; and m, n, x, and y are each independently selected from an integer of 0-1000,
provided that at least two of -QR for each of structures (i) to (xii) are —SH.

US Pat. No. 9,697,460

BIOLOGICAL ANALOG-TO-DIGITAL AND DIGITAL-TO-ANALOG CONVERTERS

Trustees of Boston Univer...

1. An analog-to-digital biological converter switch, the biological converter switch comprising at least two nucleic acid
modules, wherein each of the at least two nucleic acid modules comprise:
an inducible promoter nucleic acid sequence (iPA) operably linked to a repressor nucleic acid sequence (RA) encoding a repressor sequence, and

a toggle switch nucleic acid (TSA), (iPA-RA-TSA)n; wherein the toggle switch nucleic acid comprises a first repressible promoter nucleic acid sequence (rP1) operably linked to and capable of driving expression of a second repressor nucleic acid sequence (R2) encoding a second repressor protein, and a second repressible promoter nucleic acid sequence (rP2) operably linked to and capable of driving expression of: (i) a first repressor nucleic acid sequence (R1) encoding a first repressor protein, and (ii) an output nucleic acid sequence encoding an output product (OP) (rP1-R2 and rP2-R1-OP), wherein the first repressible promoter nucleic acid sequence rP1 is capable of being inhibited by the first repressor protein and the second repressible promoter nucleic acid sequence rP2 is capable of being inhibited by the second repressor protein, and

wherein the inducible nucleic acid promoter nucleic acid sequence of each of the at least two nucleic acid modules has a different
threshold for induction by a same inducing agent.

US Pat. No. 10,287,701

NANOPARTICLE DEPOSITION IN POROUS AND ON PLANAR SUBSTRATES

The Trustees of Boston Un...

1. A method of preparing a metal nanoparticle in or on a surface comprising:subjecting a metal to a temperature and a pressure in a carrier gas selected to provide a vapor metal species at a vapor partial pressure in the range of about 10?4 to about 10?11 atm, wherein the vapor metal species comprises one or more of vaporized metal, metal oxyhydroxides and metal hydroxides;
transporting the vapor metal species in the carrier gas to a heated substrate, wherein the heated substrate is at a temperature that is lower than the temperature to which the metal is subjected; and
depositing the metal as a nanoparticle on the heated substrate.

US Pat. No. 9,815,845

INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS

TRUSTEES OF BOSTON UNIVER...

1. A compound of formula (III?), wherein the Formula (III?) has the structure:

wherein:
R1? is an aryl substituted with at least one C1-C6 alkoxyl and at least one di(C1-C24alkyl)amino, wherein the substituted aryl can be optionally further substituted with halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 heteroalkyl, di(C1-C24alkyl)amino or combinations thereof;

R2 and R3 are hydrogen or R2 and R3 together form a second bond between the carbons to which they are attached;

R4 is hydrogen;

R5 is selected from the group consisting of hydrogen and C1-C6 alkyl;

R6 and R7 are each independently selected from the group consisting of hydrogen, F, Br, Cl and I;

R10 and R11 are each independently selected from the group consisting of hydrogen, F, Br, Cl, and I;

or enantiomers, prodrugs, derivatives, and pharmaceutically acceptable salts thereof, and wherein the compound is capable
of inhibiting late SV40 factor (LSF).

US Pat. No. 10,174,385

ASSAYS AND METHODS RELATING TO THE TREATMENT OF MELANOMA

TRUSTEES OF BOSTON UNIVER...

1. A method of treatment for melanoma, the method comprising:(a) performing quantitative duplex RT-PCR on a sample obtained from a subject to measure:
(1) the level of neurophilin-2 (NRP-2) in the sample; and
(2) a known quantity of an internal control nucleic acid added to the sample; and normalizing the level of NRP-2 to the level of the internal control nucleic acid;
(b) performing quantitative duplex RT-PCR on a sample obtained from the subject to measure:
(1) the level of melan-A (MART) in the sample; and
(2) a known quantity of an internal control nucleic acid added to the sample; and normalizing the level of MART to the level of the internal control nucleic acid;
(c) calculating the value of NRP-2:MART from the levels obtained in steps (a) and (b); and
(d) (i) surgically removing the melanoma and administering adjuvant therapy and follow-up monitoring if the value of NRP-2: MART is increased at least 2 ? relative to a reference level; and
(ii) surgically removing the melanoma and not administering adjuvant therapy if the value of NRP-2:MART is not increased at least 2 ? relative to a reference level.

US Pat. No. 10,175,476

SOLID IMMERSION MICROSCOPY SYSTEM WITH DEFORMABLE MIRROR FOR CORRECTION OF ABERRATIONS

Trustees of Boston Univer...

1. A solid immersion microscopy system comprising:a light path configured to transmit illumination from an object to be imaged;
an objective lens assembly disposed on the light path;
a solid immersion lens disposed on the light path between the objective lens assembly and the object to be imaged, the solid immersion lens including a surface configured to make optical contact with a substrate, the object to be imaged disposed on an opposite side of the substrate, the solid immersion lens further including a convex surface facing the objective lens;
a deformable mirror assembly on the light path to receive light transmitted from the object, the deformable mirror assembly comprising a mirror surface and a plurality of actuators, each actuator individually actuatable to act in concert to define a shape of the mirror surface, and
a control system in communication with the deformable mirror assembly to provide individual actuation of each of the actuators so as to correct aberrations in the light transmitted from the object by actuation of the deformable mirror assembly to change the shape of the mirror surface, wherein the aberration is caused by the light transmitted from the object interacting with the solid immersion lens.
US Pat. No. 10,802,021

SYNTHETIC HYBRID RECEPTOR AND GENETIC CIRCUIT IN BACTERIA TO DETECT ENTERIC PATHOGENIC MICROORGANISMS

Massachusetts Institute o...

1. An engineered microorganism comprisinga hybrid receptor comprising at least the binding portion of a CqsS polypeptide and a heterologous histidine kinase domain of a two-component system; and
a genetic circuit responsive to the heterologous histidine kinase.

US Pat. No. 9,399,644

[1,3] DIOXOLO [4,5-G] QUINOLINE-6(5H)THIONE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER

Trustees of Boston Univer...

1. A compound of structural formula XI, XII or XIII:
or a pharmaceutically acceptable salt thereof wherein,
each X is independently O or S;
R1 is hydrogen or an alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;

R2 is hydrogen or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group;

each R3 and each R6 is: (i) independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl,
aryl, heteroaryl or arylalkyl group; or (ii) the two R6 moieties and/or the two R3 moieties taken together with an alkylene, alkenylene or alkynylene group form a substituted or unsubstituted C3 to C6 ring;

R4, R5, R7, R8, R9, R10 and R11 are each independently hydrogen, fluorine, chlorine, bromine, iodine or a hydroxyl, alkoxy, phenoxy, alkyl, alkenyl, alkynyl,
aryl, heteroaryl or arylalkyl group; and

R13 is hydrogen or an alkyl, alkenyl, alkynyl, aryl, heteroaryl or arylalkyl group.

US Pat. No. 9,872,936

INJECTABLE TISSUE SUPPLEMENT

Trustees of Boston Univer...

1. An aqueous solution comprising a polymer dissolved therein, wherein the polymer in the aqueous solution comprises: (a)
one or more monomers selected from compounds of Formulas I and II; and (b) one or more monomers selected from compounds of
Formula XXXV, wherein compounds of Formulas I and II are:

wherein:
R1, R2, R4, R5, R6, R7, R11, R12, R13, and R14 are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, H, halide, ether-linked alkyl, ether-linked
alkenyl, ether-linked alkynyl;

R8, R9 and R10 are independently alkyl;

R3 is selected from the group consisting of hydrogen, a straight or branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl,
arylsilyl, alkylaryl, arylalkyl, methoxy, ethoxy, amino, or fluorocarbon chain of 1-50 carbons, wherein each alkyl, cycloalkyl,
aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, arylalkyl, or fluorocarbon chain is optionally substituted internally
or terminally by one or more hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or di-substituted
amino, thiol, thioester, sulfate, phosphate, phosphonate, or halogen substituents;

X is O;
Q1, Q2 and Q3 are each C;

E1, E2, E3, E4, E5 are each O;

n and m can each independently range from 0-14; and
m is 1-14;compounds of Formulas XXXV are:
wherein:
R1, R2, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, H, halide, ether-linked alkyl, ether-linked
alkenyl, ether-linked alkynyl;

R3 is selected from the group consisting of hydrogen, a straight or branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl,
arylsilyl, alkylaryl, arylalkyl, methoxy, ethoxy, amino, or fluorocarbon chain of 1-50 carbons, wherein each alkyl, cycloalkyl,
aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, arylalkyl, or fluorocarbon chain is optionally substituted internally
or terminally by one or more hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or di-substituted
amino, thiol, thioester, sulfate, phosphate, phosphonate, or halogen substituents;

Q1, Q2, Q3 and Q4 are each C;

E1 and E2 are each O; and

a is an integer from 0-1200.
US Pat. No. 9,814,761

COMPOSITIONS, METHODS AND ASSAYS COMPRISING AMYLIN OR AMLYIN ANALOGS FOR ABETA-PEPTIDE MEDIATED DISORDERS

TRUSTEES OF BOSTON UNIVER...

1. A method for inhibiting progression of Alzheimer's disease or amnestic mild cognitive impairment, the method comprising
administering to a subject having Alzheimer's disease or amnestic mild cognitive impairment a therapeutically effective amount
of an amylin or amylin analog, wherein the amylin analog has a sequence selected from the group consisting of SEQ ID NOs:
13-44; and obtaining a biological sample from the subject within 72 hours of said administering and measuring the amount or
quantity of A? peptide in the biological sample.

US Pat. No. 9,072,428

CLASSIFICATION TECHNIQUES FOR MEDICAL DIAGNOSTICS USING OPTICAL SPECTROSCOPY

TRUSTEES OF BOSTON UNIVER...

1. A system configured to classify a tissue pathology comprising:
an optical probe configured to measure the biomedical optical spectra data from a tissue; and
a classification system coupled to the optical probe comprising a plurality of support vector machines with embedded error
rejection to classify the biomedical optical spectra data from the tissue; wherein each of the plurality of the support vector
machines with embedded error rejection is configured to classify a different region of the optical spectra data from the tissue,
the classification comprising:

using feature selection to determine the regions of greatest difference between the average spectrum for dysplastic and non-dysplastic
tissues

classifying a first region of the biomedical optical spectra data from the tissue using a first classifier;
classifying a second region of the biomedical optical spectra data from the tissue using a second classifier, the first region
being different than the second region; and

combining the classification of the first classifier with the classification of the second classifier to determine a classification
of the tissue, wherein the first and the second classifier cover optical spectra data from wavelength 330-600 nm and/or 330-400
nm;

wherein the classification of the first classifier and the classification of the second classifier is selected from the group
consisting of positive, negative and rejected.

US Pat. No. 10,543,313

GLUCOSE LEVEL CONTROL SYSTEM WITH OFFLINE CONTROL BASED ON PRECEDING PERIODS OF ONLINE CONTROL

Trustees of Boston Univer...

1. A glucose level control system, comprising:a glucose sensor operative to continually measure a glucose level of a subject and generate a corresponding glucose level signal;
an insulin delivery device operative in response to an insulin dose control signal to infuse insulin into the subject; and
a controller having online operation and offline operation to generate the insulin dose control signal to achieve and maintain euglycemia in the subject, online operation employing a control algorithm including (i) regular administration of correction doses of insulin based on control parameters of the control algorithm and regular periodic sampling of glucose levels via the glucose sensor, and (ii) autonomously adjusting the control parameters to tailor the control parameters to the subject, offline operation including (iii) evolving a state of the control algorithm over time without sampling of glucose levels and without automatic administration of the correction doses of insulin, and (iv) correction dosing operations each including administration of a correction dose of insulin in response to an isolated glucose measurement provided to the controller, the correction dose being calculated by the controller based on the isolated glucose measurement, the control parameters, and the state of the control algorithm as evolved at the time of the correction dosing operation.
US Pat. No. 10,041,044

AGE-ASSOCIATED CLONAL HEMATOPOIESIS ACCELERATES CARDIO-METABOLIC DISEASE DEVELOPMENT

TRUSTEES OF BOSTON UNIVER...

1. A method for treating a subject having a TET2 mutation-mediated cardiometabolic disease or disorder comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a blocking IL-1? inhibitor antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier to a subject having one or more inactivating TET2 mutations in a sub-population of peripheral blood hematopoietic cells.

US Pat. No. 9,567,331

PYRIDOPYRIMIDINONE INHIBITORS OF VIRUSES

Trustees of Boston Univer...

1. A pharmaceutical composition comprising a pyridopyrimidinone viral inhibitor of chemical structure:

US Pat. No. 9,550,987

RIBOREGULATOR COMPOSITIONS AND METHODS OF USE

President and Fellows of ...

1. A toehold riboregulator comprising
an RNA comprising in a 5? to 3? order
(1) a single-stranded toehold domain,
(2) a fully or partially double-stranded stem domain comprising
(i) an initiation codon, and
(ii) a loop domain comprising a ribosome binding site, and
(3) a coding domain.
US Pat. No. 10,093,979

POLYMORPHISM OF THROMBOSPONDIN-1 AS A BIOMARKER FOR SUSCEPTIBILITY TO DRY EYE

Trustees of Boston Univer...

1. A method for treatment of dry eye comprising:a. obtaining a biological sample from an individual,
b. detecting the presence of at least one single nucleotide polymorphism (SNP) in the THBS1 gene in the biological sample using a method selected from the group consisting of: single-strand conformational polymorphism (SSCP) analysis, long range polymerase chain reaction (PCR) and allele specific hybridization, wherein the SNP is selected from the group consisting of: the presence of a cytosine “C” allele at position 42 of SEQ ID NO: 1, or its complement thereof (SNP1); the presence of a thymine “T” allele at position 7079 of SEQ ID NO: 1, or its complement thereof (SNP2); and the presence of a guanine “G” allele at position 7543 of SEQ ID NO: 1, or its complement thereof (SNP3), and
c. administering to an individual who has at least one SNP as determined in step (b), a pharmaceutically effective amount of a dry eye therapeutic.
US Pat. No. 10,857,152

METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS

TRUSTEES OF BOSTON UNIVER...

1. A method for treating and/or preventing a viral or virally-induced condition comprising administering CHR-3996, wherein the CHR-3996 is administered at less than 2 mg/kg per dose, and an antiviral agent, wherein the antiviral agent is selected from the group consisting of valganciclovir, ganciclovir, acyclovir, famciclovir, and combinations thereof, wherein the viral or virally-induced condition is caused by a DNA virus.

US Pat. No. 9,979,038

SYSTEM AND METHOD FOR ENERGY STORAGE AND RECOVERY

Trustees of Boston Univer...

1. An apparatus for storing and recovering electrical energy, the apparatus comprising:a reversible solid oxide electrochemical cell (RSOEC) that comprises a porous cathode, a porous anode, and an electrolyte capable of transporting oxygen ions;
a reactor comprising a powder bed that includes tungsten, tungsten oxide, or combinations thereof;
wherein the RSOEC is configured to receive electrical energy to electrolyze H2O to generate H2 and O2 and the reactor is operably connected to the RSOEC to receive the generated H2 and convert tungsten oxide to tungsten thereby storing electrical energy in the form of tungsten; and
wherein the reactor is configured to receive H2O to convert tungsten to tungsten oxide and generate H2 and the RSOEC is operably connected to the reactor to receive the generated H2 and generate electrical energy and H2O thereby recovering electrical energy from tungsten,
wherein the apparatus further comprises a heat exchanger;
wherein the heat exchanger is configured to receive heat from the reactor when the reactor receives H2O to convert tungsten to tungsten oxide and generate H2, and wherein the heat exchanger is configured to receive heat from the RSOEC when the RSOEC generates electrical energy and H2O; and
wherein the heat exchanger is configured to provide heat to the RSOEC when the RSOEC electrolyzes H2O to generate H2 and O2, and wherein the heat exchanger is configured to provide heat to the reactor when the reactor converts tungsten oxide to tungsten.
US Pat. No. 9,957,511

FUNCTIONALIZATION OF ENDOGENOUS BACTERIA

Massachusetts Institute o...

1. A method of functionalizing endogenous Escherichia coli (E. coli) in a subject, the method comprising delivering to a subject having an inflammatory bowel disease, non-lytic recombinant Inoviridae M13 coliphage thatare not comprised within a bacterial cell during delivery,
infect viable nonpathogenic endogenous E. coli present in the subject, and
are engineered to contain at least one nucleic acid comprising an inducible promoter operably linked to a nucleotide sequence that encodes an interleukin (IL),
to produce viable nonpathogenic functionalized E. coli in the subject.
US Pat. No. 10,080,766

PROTON-MOTIVE FORCE STIMULATION TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS AGAINST PERSISTENT BACTERIA

TRUSTEES OF BOSTON UNIVER...

1. A method for treating a bacterial infection associated with a urinary catheter, comprising:administering to a subject in need thereof, by intravenous administration, an effective amount of an aminoglycoside antibiotic selected from the group consisting of gentamicin and amikacin, and an effective amount of pyruvate as a proton-motive force stimulating metabolite.

US Pat. No. 10,101,315

CHEMICAL FUNCTIONALIZATION OF SOLID-STATE NANOPORES AND NANOPORE ARRAYS AND APPLICATIONS THEREOF

TRUSTEES OF BOSTON UNIVER...

1. A method for characterizing nucleotide sequences of mixtures of DNA molecules comprising:providing an optically-addressable nanopore array comprising a solid-state electrically insulating membrane having a plurality of apertures each aperture having a surface with an organic monolayer coating and a protein nanopore immobilized therein by the organic monolayer coating;
receiving fluorophore-labeled DNA molecules through the nanopores;
optically probing the nanopore array; and
detecting variations in fluorescence from the fluorophore-labeled DNA molecules at each nanopore, the variations in fluorescence being indicative of a nucleotide sequence of a fluorophore-labeled DNA molecule as it translocates through a nanopore.
US Pat. No. 10,040,856

ANTI-DESPR INHIBITORS AS THERAPEUTICS FOR INHIBITION OF PATHOLOGICAL ANGIOGENESIS AND TUMOR CELL INVASIVENESS AND FOR MOLECULAR IMAGING AND TARGETED DELIVERY

TRUSTEES OF BOSTON UNIVER...

1. An isolated antibody or antigen-binding fragment thereof that specifically binds DEspR (dual endothelin/VEGF signal peptide receptor) of SEQ ID NO: 1 and comprises a VH domain comprising a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 5; a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 6; and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:7 and a VL domain comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 10; a light chain CDR2 having the amino acid sequence of SEQ ID NO: 11; and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 12.

US Pat. No. 10,004,695

GM3 FUNCTIONALIZED NANOPARTICLES

Trustees of Boston Univer...

1. A nanoparticle comprising:a) a core having a largest diameter between 50-90 nm;
b) a coating layer encasing the core, wherein the core comprises a material selected from the group consisting of gold, silver, a gold alloy, a silver alloy, silica, mesoporous silica, polystyrene, and titania; and
c) a ganglioside GM3-containing mixed lipid layer comprising of dipalmitoylphosphatidylcholine (DPPC), cholesterol, phosphatidylserine (PS), and aNeu5Ac(2-3)bDGalp(1-4)bDG1cp(1-1)Cer (GM3); wherein the ganglioside GM3-mixed lipid layer is exterior of the coating layer and is integrated into the coating layer, and wherein the nanoparticles have an overall particle size between 60-100 nm.

US Pat. No. 10,392,134

PROPULSION AND GAS-MOVING SYSTEMS USING TRAVELLING-WAVE GAS DIELECTROPHORESIS

Trustees of Boston Univer...

1. A traveling-wave dielectrophoresis propulsion system for an orbiting vehicle, comprising:a set of surfaces over which a gas passes during orbital flight of the vehicle;
a plurality of electrodes on the surfaces, the electrodes configured to create an electric field having a predetermined spatial field pattern in response to field signals applied thereto, the spatial field pattern being experienced by passing molecules of the gas as an oscillating field having a frequency on the order of a polarization-resonance frequency of the molecules to impart a propulsive traveling-wave dielectrophoretic force to the passing molecules, the electrodes extending over sufficient area to impart sufficient traveling-wave dielectrophoretic force to the gas to overcome aerodynamic drag and thereby sustain orbital flight of the vehicle; and
a power source configured and operative to apply the field signals to the electrodes, the power source providing sufficient power to overcome power lost to aerodynamic drag and thereby sustain orbital flight of the vehicle.
US Pat. No. 10,233,498

THERAPEUTIC AGENT FOR EMPHYSEMA AND COPD

TRUSTEES OF BOSTON UNIVER...

1. A method comprising:detecting the level of expression of at least 1 mRNA of each of ATPase secretory pathway Ca2+ transporting 2 (ATP2C2), carboxylesterase 3 (CES3); Protein kinase C epsilon (PRKCE); Reticulon 4 (RTN4); and HECT and RLD domain containing E3 ubiquitin protein ligase 3 (HERC3) in a sample obtained from a subject, wherein the level of expression of no more than 400 genes is determined.

US Pat. No. 10,151,680

NANOPARTICLES FOR SELF REFERENCING CALIBRATION

TRUSTEES OF BOSTON UNIVER...

1. An assay plate comprising(i) a base layer having a first reflective surface;
(ii) a transparent layer having a first surface in contact with the first reflective surface of the base layer, and a second surface providing a second reflective surface on the opposite side of the first surface, whereby the first and second reflective surfaces create an optical path length difference for light illuminating the assay plate; and
(iii) at least one calibration nanoparticle having a pre-defined size immobilized in close proximity to the second surface of the transparent layer, whereby upon illumination, the sizes of the calibration nanoparticles can be determined as a function of the reflected light signal, and whereby the calibration nanoparticles are used as markers for autofocusing.

US Pat. No. 9,927,350

THERMAL PROPERTY MICROSCOPY WITH FREQUENCY DOMAIN THERMOREFLECTANCE AND USES THEREOF

TRUSTEES OF BOSTON UNIVER...

1. A method of performing a frequency domain thermoreflectance measurement, the method comprising:(i) projecting a first beam of radiation onto a sample while a heat source is applied to the sample, wherein the heat source is modulated at a modulation frequency;
(ii) measuring reflected radiation from the first beam of radiation at at least two modulation frequencies simultaneously, wherein amplitude and/or phase data of the reflected radiation are obtained, and wherein the modulation frequencies are determined from sensitivity of amplitude and/or phase of the reflected radiation to a given thermophysical property;
(iii) repeating steps (i) and (ii) at a plurality of spots in the sample; and
(iv) producing a two-dimensional (2D) image of at least one thermophysical property of the sample based on the measurements.

US Pat. No. 10,604,784

METHOD AND DEVICE FOR ANTIBIOTIC SUSCEPTIBILITY TESTING BASED ON FLUCTUATIONS OF ELECTRICAL RESISTANCE IN A MICROCHANNEL

Trustees of Boston Univer...

1. A method for detecting live bacteria in a microchannel comprising:a) providing a constant current or constant voltage through a microchannel wherein the microchannel does not contain any bacteria and measuring baseline resistance through the microchannel to determine a baseline resistance fluctuation signal;
b) providing a constant current or constant voltage through a microchannel wherein the microchannel contains at least one bacterium and measuring resistance fluctuations through the microchannel to determine a first resistance fluctuation signal; and
c) determining that the at least one bacterium is alive if the first resistance fluctuation signal is greater than the baseline resistance fluctuation signal by a predefined threshold amount.

US Pat. No. 10,251,841

POLYMERIC DEPOTS FOR LOCALIZATION OF AGENT TO BIOLOGICAL SITES

TRUSTEES OF BOSTON UNIVER...

1. A method of administering an agent to a tissue location in a subject, the method comprising administering to the subject polymeric particle prior to, or after administering said agent to the subject, wherein said agent is administered without the polymeric particle and the polymeric particle does not include any therapeutic agent or diagnostic agent when the polymeric particle is administered,wherein the polymeric particle comprises an oligomer or a polymer comprising a monomer represented by Formula XX:

wherein:
Q is selected from the group consisting of O, S, Se, and NH;
G is selected from the group consisting of the following structures:

R2 is selected from the group consisting of hydrogen, a straight or branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, arylalkyl, and fluorocarbon chain of 1-50 carbons, wherein each alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, arylalkyl, or fluorocarbon chain is optionally substituted internally or terminally by one or more hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or di-substituted amino, thiol, thioester, sulfate, phosphate, phosphonate, or halogen substituents;
one R3 is selected from the group consisting of methoxy, ethoxy, amino, nitro, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, and arylalkyl chain of 1-10 carbons;
and the remaining R3 are each independently selected from the group consisting of hydrogen, methoxy, ethoxy, amino, a straight and branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, and arylalkyl chain of 1-10 carbons;
R4, R5, and R6 are each independently selected from the group consisting of a straight or branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, and arylalkyl chain of 1-10 carbons; and
R7 and R8 are each independently selected from the group consisting of hydrogen, a straight or branched alkyl, cycloalkyl, aryl, olefin, alkylaryl, and arylalkyl chain of 1-50 carbons, wherein each alkyl, cycloalkyl, aryl, olefin, alkylaryl, or arylalkyl chain is optionally substituted internally or terminally by one or more hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or di-substituted amino, thiol, thioester, sulfate, phosphate, phosphonate, or halogen substituents.

US Pat. No. 10,188,795

BLOOD GLUCOSE CONTROL SYSTEM

Trustees of Boston Univer...

1. A sensor-driven glucose control system, comprising:an insulin delivery device operative in response to an insulin dose control signal to infuse insulin into the subject; and
a controller operative to generate the insulin dose control signal by:
(1) continually administering priming doses of insulin at respective times, each priming dose being of a respective amount and having a prescribed interval of action;
(2) receiving information regarding total amounts of insulin administered during the prescribed intervals of action, each total amount including an aggregation of total doses administered in response to a glucose level signal; and
(3) automatically adapting the amounts of the priming doses in response to a mathematical relationship, over respective periods each spanning multiple prescribed intervals of action, between the amounts of the priming doses and the total amounts of insulin administered during the prescribed intervals of action.
US Pat. No. 10,138,493

SYNTHETIC TRANSCRIPTIONAL AND EPIGENETIC REGULATORS BASED ON ENGINEERED, ORTHOGONAL ZINC FINGER PROTEINS

TRUSTEES OF BOSTON UNIVER...

1. An engineered responsive promoter comprising (a) at least one target DNA sequence element selected from the group consisting of 5?-CGTCGAAGTCGAAGTCGACC-3? (SEQ ID NO: 81), 5?-GGACGACGTTACGGACGTAC-3? (SEQ ID NO: 82), 5?-A GACGTCGAAGTAGCCGTAG-3? (SEQ ID NO: 83), 5?-GGACGACGCCGATGTAGAAG-3? (SEQ ID NO: 84), 5?-TGAAGCAGTCGACGCCGAAG-3? (SEQ ID NO: 85), 5?-GGACGACGCGGTCTAAGAAG-3? (SEQ ID NO: 86), 5?-CGACGAGGTCGCATAAGTAG-3? (SEQ ID NO: 87), 5?-AGACGCAGTATAGGTCGAAC-3? (SEQ ID NO: 88), 5?-AGACGCAGTATAGGACGACG-3? (SEQ ID NO: 89), 5?-CGGCGTAGCCGATGTCGCGC-3? (SEQ ID NO: 90), and 5?-GGTCGTTGCGGTAGTCGAAG-3? (SEQ ID NO: 91) and (b) a promoter sequence, wherein the at least one target DNA sequence element is operably linked at the 5? end of the promoter sequence in order to influence transcription initiation of a nearby coding sequence.
US Pat. No. 10,676,721

BACTERIOPHAGES EXPRESSING ANTIMICROBIAL PEPTIDES AND USES THEREOF

Trustees of Boston Univer...

1. An engineered bacteriophage comprising a heterologous nucleic acid operatively linked to a promoter, wherein the nucleic acid encodes at least one antimicrobial polypeptide fused to an N-terminal secretory signal sequence, the antimicrobial peptide having antimicrobial properties when outside a bacterial cell.
US Pat. No. 10,564,107

STRUCTURED SUBSTRATES FOR OPTICAL SURFACE PROFILING

TRUSTEES OF BOSTON UNIVER...

1. An optical detection apparatus comprising:(i) a reflective substrate having an uppermost surface, the reflective substrate comprising capture molecules adsorbed or covalently bound to the uppermost surface;
(ii) a tunable light source positioned above the reflective substrate, the tunable light source comprising an illumination beam having a tuning range of light comprising varying wavelengths, the illumination beam being directed substantially perpendicular to the uppermost surface of the substrate; and
(iii) a photodetector array operably linked to a central processor configured to measure an intensity of light reflected from the substrate.

US Pat. No. 10,538,439

METHOD AND COMPOSITION FOR REDUCING NITRATES, NITRITES, AND/OR HYDROXYLAMINE IN WATER USING A HOMOGENEOUS REDUCED COPPER TETRA-SUBSTITUTED FLUORINATED PINACOLATE LIGAND CATALYST COMPLEX

Trustees of Boston Univer...

1. A method for reducing nitrates, nitrites, and/or hydroxylamine in water using a homogeneous reduced copper tetra-substituted fluorinated pinacolate ligand catalyst complex, the method comprising:dissolving a copper(II) tetra-substituted fluorinated pinacolate ligand pre-catalyst complex in water having an excess amount of nitrates, nitrites, and/or hydroxylamine therein;
subjecting the dissolved copper(II) tetra-substituted fluorinated pinacolate ligand pre catalyst complex in the water to electrochemical reduction to form a homogeneous reduced copper tetra-substituted fluorinated pinacolate ligand catalyst complex; and
reducing the nitrates, nitrites, and/or hydroxylamine in the water to compounds with nitrogen in a lower oxidation state with the homogeneous reduced copper tetra-substituted fluorinated pinacolate ligand catalyst complex.

US Pat. No. 10,535,801

HIGH EFFICIENCY ULTRAVIOLET LIGHT EMITTING DIODE WITH BAND STRUCTURE POTENTIAL FLUCTUATIONS

Trustees of Boston Univer...

1. A device comprising:an AlGaN quantum well (QW) active layer disposed between an n-type region and a p-type region, wherein the QW active layer emits ultraviolet radiation in a wavelength range between 210 nm and 360 nm and is undoped, the QW active layer having a first AlN mole fraction and a first bandgap;
a QW barrier layer adjacent to the QW active layer, the QW barrier layer being between the QW active layer and the n-type region, the QW barrier layer having a second AlN mole fraction higher than the first AlN mole fraction so as to have a second bandgap higher than the first bandgap of the QW active layer; and
a first layer adjacent to the QW barrier layer and in the n-type region having a third bandgap smaller than the first bandgap of the QW active layer, wherein the first layer is doped with an n-type dopant, the first layer having a third AlN mole fraction that is less than the first AlN mole fraction; and
a second layer in the n-type region and adjacent to the first layer, wherein the second layer has a fourth AlN mole fraction larger than the first AlN mole fraction of the QW active layer, the second AlN mole fraction of the QW barrier layer, and the third AlN mole fraction of the first layer,
the second layer also having a fourth band gap larger than the first bandgap of the QW active layer, the second bandgap of the QW barrier layer, and the third bandgap of the first layer; and
a third layer in the n-type region and adjacent to the second layer, the third layer having a fifth AlN mole fraction lower than the first AlN mole fraction and a fifth bandgap lower than the first bandgap of the QW active layer,
wherein electrons in the first layer tunnel through the QW barrier layer into the QW active layer when the device is energized.

US Pat. No. 10,400,064

GLYCEROL-BASED POLYCARBONATES

Trustees of Boston Univer...

1. A linear, comb, branched, or dendrite oligomer or polymer comprising the following formula:
wherein each Q? is independently selected from among: O, S, Se, or NH;
wherein each G? is independently is independently selected from the following structures:
andwherein R1? is selected from among hydrogen, a straight or branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl or arylalkyl chain of 1-50 carbons, wherein each alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, fluorocarbon, succinyl, or arylalkyl chain is optionally substituted internally or terminally by one or more hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or di-substituted amino, thiol, thioester, sulfate, phosphate, phosphonate, or halogen substituents, poly(ethylene glycol), poly(ethylene oxide), poly(hydroxyacid)), a carbohydrate, a protein, a polypeptide, an amino acid, a nucleic acid, a nucleotide, a polynucleotide, any DNA or RNA segment, a lipid, a polysaccharide, an antibody, a pharmaceutical agent, or any epitope for a biological receptor, a photocrosslinkable or ionically crosslinkable group;
wherein n is selected from an integer of 1-1,000; and
wherein each polymeric terminal group is selected from among amines, thiols, amides, phosphates, sulphates, hydroxides, metals, alkanes, alkenes, and alkynes.

US Pat. No. 10,392,398

INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS

TRUSTEES OF BOSTON UNIVER...

1. A method for reducing cell proliferation in a cancer that overexpresses LSF in a subject, the method comprising administering an effective amount of a compound of Formula (III?) to a subject in need thereof, wherein the Formula (III?) has the structure:
wherein:
R1? is an aryl substituted with at least one C1-C6 alkoxyl and at least one di(C1-C24alkyl)amino, halogen or C2-C8alkenyl;
R2 and R3 are hydrogen;
R4 is hydrogen;
R5 is hydrogen;
R6 and R7 are hydrogen;
R10 and R11 are hydrogen;
and pharmaceutically acceptable salts thereof, and wherein the compound is capable of inhibiting late SV40 factor (LSF).

US Pat. No. 10,258,268

HIGH-SPEED TISSUE OXIMETRY SYSTEM EMPLOYING FAST DIGITAL DIFFUSE OPTICAL SPECTROSCOPY

Trustees of Boston Univer...

1. A tissue oximetry system, comprising:an optical subsystem including a plurality of optical sources and one or more optical detectors, the optical sources being configured and operative to generate a set of optical signals of distinct wavelengths modulated according to respective RF modulation signals applied thereto, the set of wavelengths and the RF modulation signals selected according to a model for (1) obtaining absorption values and scattering values from per-wavelength amplitude and phase responses, and (2) obtaining measurements of blood oxygen values from the absorption and scattering values for the wavelengths, the optical signals collectively forming an incident optical signal configured to be directed to a sample location of a tissue, the one or more optical detectors being configured and operative to generate one or more analog detection signals indicative of amplitude and phase of RF modulation components of a detected optical signal emanating from the sample location in response to the incident optical signal; and
an electronics and processing subsystem including a set of signal sources, an analog-to-digital conversion circuit, data acquisition circuitry, and a processor, the signal sources being configured and operative to generate respective ones of the RF modulation signals based on corresponding RF modulation command values from the processor, the analog-to-digital conversion circuit being configured and operative to generate respective streams of raw digital sample values from the analog detection signals, the data acquisition circuitry and processor being co-configured and co-operative to:
(1) provide the RF modulation command values to the signal sources in synchronism with sampling operation of the analog-to-digital conversion circuit and according to an offset pattern and rate that includes stepping through an RF range for each of the RF modulation signals according to the model, using a predetermined step size, the stepping being performed at a sufficiently high rate to obtain measurements of the absorption value and the scattering value for each of the wavelengths in each of respective measurement intervals at least 10 times per second, and
(2) in each of the measurement intervals, calculate the model to obtain one or more respective blood oxygen values from the respective measurements of the absorption values and scattering values of the measurement interval, and display or otherwise use the obtained blood oxygen values in higher-level diagnostic assessment of the blood oxygenation of the tissue.
US Pat. No. 10,202,457

ANTI-DESPR MONOCLONAL ANTIBODY TARGETED THERAPY AND IMAGING FOR CANCER AND STROKE

TRUSTEES OF BOSTON UNIVER...

1. An isolated antibody or antigen-binding fragment thereof capable of binding to DEspR (dual endothelin-1/VEGF signal peptide receptor) of SEQ ID NO: 3 comprising heavy and light chain sequences comprising complementarity determining regions (CDRs) of a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 14; a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 15; a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 16; a light chain CDR1 having the amino acid sequence of SEQ ID NO: 28; a light chain CDR2 having the amino acid sequence of SEQ ID NO: 29; and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 30.

US Pat. No. 10,184,888

DEVICE AND METHOD FOR DETERMINING A REFRACTIVE INDEX

TRUSTEES OF BOSTON UNIVER...

1. A device for determining a refractive index or a hydrophone, comprising:at least one waveguide having a core and a cladding surrounding the core, the cladding being at least partly removed in at least one first longitudinal portion and the core containing in at least one second longitudinal portion at least one fiber Bragg grating, at least one partial area of a surface being provided in the at least one first longitudinal portion with nanoparticles, wherein the nanoparticles contain a metal or an alloy and have a plasmon frequency which corresponds approximately to a resonance frequency of the at least one fiber Bragg grating; and
an apparatus for detecting the intensity of light reflected by the at least one fiber Bragg grating.

US Pat. No. 10,090,426

DARK CURRENT MITIGATION WITH DIFFUSION CONTROL

Trustees of Boston Univer...

1. A photosensor device comprising:a photon absorbing layer;
at least two photosensor diffusions in said absorbing layer,
said at least two photosensor diffusions in said absorbing layer having the edges of the diffusions thereof separated in said absorbing layer by less than two minority carrier diffusion lengths; and
at least one diffusion control junction diffusion in said absorbing layer in proximity to two photosensor diffusions, wherein any said diffusion control junction diffusion forms a homojunction with said photon absorbing layer.
US Pat. No. 10,011,875

METHODS AND ASSAYS RELATING TO HUNTINGTONS DISEASE AND PARKINSON'S DISEASE

Trustees of Boston Univer...

1. A method comprising detecting the level of expression of at least 1 of miR520f-3p, miR-135b-3p, miR-4317, miR-3928-5p, miR-8082, mir-140-5p in a sample obtained from a subject having an htt mutation.

US Pat. No. 9,780,254

ULTRAVIOLET LIGHT EMITTING DIODE STRUCTURES AND METHODS OF MANUFACTURING THE SAME

Trustees of Boston Univer...

1. A light emitting device comprising:
a semiconductor structure comprising a III-nitride active region disposed between an n-type region and a p-type region, wherein
the active region is configured to emit electromagnetic radiation in an ultraviolet wavelength range;

wherein the active region comprises a plurality of quantum well layers separated by a plurality of separation layers;
wherein thicknesses of the plurality of separation layers form a gradient between the n-type region and the p-type region;
wherein the plurality of separation layers are configured to have a first mode to act as a barrier region for separating a
plurality of carriers in a quantum confined mode in each of the plurality of quantum well layers being provided on each side
of the plurality of separation layers, and a second mode configured to cause spreading of the plurality of carriers across
each of the plurality of quantum well layers to increase an overlap integral of the plurality of carriers from a first value
to a second value, the second value being greater than the first value, the first value being associated with the first mode
and the second value being associated with the second mode.

US Pat. No. 9,624,554

MODULAR NUCLEIC ACID-BASED CIRCUITS FOR COUNTERS, BINARY OPERATIONS, MEMORY, AND LOGIC

Trustees of Boston Univer...

1. A single invertase memory module (SIMM) engineered nucleic acid molecule comprising a nucleic acid sequence encoding: a
forward recombinase recognition site (RRSfor), an inverted promoter sequence (iPinv), a recombinase sequence (RC), a reverse recombinase recognition site (RRSrev), [RRSfor-iPinv-RC-RRSrev],a ribosome binding site (RBS), a protein degradation tag sequence (D), and a transcriptional terminator sequence (T), where
the recombinase encoded by the recombinase sequence is specific for the forward and reverse recombination recognition sites.

US Pat. No. 10,491,305

SYSTEM AND METHOD FOR EMBEDDING PHASE AND AMPLITUDE INTO A REAL-VALUED UNIPOLAR SIGNAL

Trustees of Boston Univer...

1. A system for embedding phase and amplitude into a real-valued unipolar signal suitable for intensity modulation (IM) by an optical transmitter, the system comprising:a data bit generator responsive to a data bit stream configured to generate data bit symbols;
a quadrature amplitude modulator (QAM) responsive to the data bit symbols configured to generate QAM symbols;
a mapper responsive to the QAM symbols configured to assign the QAM symbols to all sub-carriers of an Inverse Fourier Transform (IFFT) engine operation with no Hermitian symmetry to double spectral efficiency;
the IFFT engine responsive to the assigned QAM symbols to all the sub-carriers configured to output complex orthogonal frequency division multiplexing (OFDM) symbols;
a complex-to-unipolar conversion engine including:
a Cartesian-to-polar converter configured to receive the complex OFDM symbols in Cartesian format output by the IFFT engine and convert the complex OFDM symbols from the Cartesian format to a polar coordinate format,
a phase and amplitude pre-equalizer responsive to the complex OFDM symbols in the polar coordinate format configured to set values of phase and amplitude of individual samples of the complex OFDM symbols in the polar coordinate format in order to optimize bit error rate under dynamic range operation constraints at a predetermined data rate and output equalized amplitude and phase samples having an embedded amplitude and phase,
wherein amplitudes of different samples of complex valued OFDM symbols are transmitted on one half of a period and phases of different samples of complex valued OFDM symbols are transmitted on the other half of the period; and
a unipolar symbol generator configured to generate real-valued unipolar OFDM symbols, including embedded phase and amplitude information, of the complex OFDM symbols in the Cartesian format without a need for Hermitian symmetry, and
the optical transmitter configured to generate an output optical signal including the real-valued unipolar OFDM symbols generated by the unipolar symbol generator.

US Pat. No. 10,391,068

PRION PROTEIN LIGANDS AS THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISORDERS

TRUSTEES OF BOSTON UNIVER...

1. A method for therapeutic treatment of Alzheimer's disease (AD), the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of:wherein said compound is capable of blocking the binding of A? oligomers to PrPC.

US Pat. No. 10,593,830

ULTRAVIOLET LIGHT EMITTING DIODE STRUCTURES AND METHODS OF MANUFACTURING THE SAME

Trustees of Boston Univer...

1. A light emitting device comprising:a semiconductor structure comprising a III-nitride active region disposed between an n-type region and a p-type region, wherein the active region is configured to emit electromagnetic radiation in an ultraviolet wavelength range;
wherein the active region comprises:
a first barrier disposed proximate the n-type region;
a first quantum well layer;
a tunable inner barrier;
a second quantum well layer; and
a last barrier disposed proximate the p-type region;
wherein the tunable inner barrier is disposed between the first and second quantum well layers, and the first and second quantum well layers are disposed between the first barrier and the last barrier, and
wherein the tunable inner barrier has a thickness less than a thickness of both the first barrier and the last barrier, where the thickness of the inner barrier is equal to or greater than 1 nm, and wherein the inner barrier is AlxGa1-xN, having a mole fraction of AlN greater than 55%, which is less than an AlN mole fraction in the first barrier and last barrier.

US Pat. No. 10,571,606

NANOANTENNA ARRAYS FOR NANOSPECTROSCOPY, METHODS OF USE AND METHODS OF HIGH-THROUGHPUT NANOFABRICATION

TRUSTEES OF BOSTON UNIVER...

1. A nanoantenna array device comprising;a. a flexible support selected from a thin film support, a sticky support or elastic support, wherein the flexible support can conform to be fitted inside a predefined shape, void or recess, or wrapped on the outside of an element;
b. a plurality of plasmonic nanostructures on the flexible support, the plasmonic nanostructures
(i) having predefined three-dimensional-shapes, each plasmonic nanostructure having a substantially consistent shape of an upper surface and a surface contacting the flexible support, where the upper surface is consistently flat and the side walls are perpendicular to the surface of the flexible support and have a vertical wall profile for localized plasmon resonance; and
(ii) arranged in a predefined periodic pattern with respect to the flexible support for diffracting an incident electromagnetic radiation, wherein the incident electromagnetic radiation forms a diffraction order that is evanescent where the wavelength of the incident electromagnetic radiation is longer than the predefined pattern's periodicity, and wherein the incident electromagnetic radiation forms a diffraction order that is radiative where the wavelength of the incident electromagnetic radiation is shorter than the predefined pattern's periodicity; and
(iii) separated by a periodicity of between ?/2-2? or ?/4-5?, wherein ? refers to the wavelength of an electromagnetic radiation; and
(iv) each plasmonic nanostructure having a consistent height of between 10-200 nm, and a consistent surface geometry.
US Pat. No. 10,568,970

THERANOSTIC COMPOSITIONS AND USES THEREOF

TRUSTEES OF BOSTON UNIVER...

1. A composition comprising: a microbubble with a Janus nanoparticle associated with the surface, wherein the Janus nanoparticle is asymmetrical and comprises an ultrasmall superparamagnetic iron oxide nanoparticle (USPION) having a nucleic acid delivery face and a targeting face, and wherein the nucleic acid delivery face and the targeting face are distinct from one another,wherein the USPION is less than 50 nm in size, and
wherein the nucleic acid delivery face comprises a nucleic acid molecule that is sandwiched between the microbubble and the Janus nanoparticle.

US Pat. No. 10,324,152

APPARATUS FOR IMPROVING MAGNETIC RESONANCE IMAGING

TRUSTEES OF BOSTON UNIVER...

1. A passive apparatus for improving operation of an MRI machine characterized by a working frequency, by improving the signal-to-noise ratio of received signals, the apparatus comprising:an array of unit cells, the array sized to be disposed within a bore of the MRI machine along with a specimen in the bore, when the MRI machine is imaging the specimen, wherein:
the unit cells are selected from the group consisting of broadside-coupled split-ring resonators, open loop coils, and helical coils,
each unit cell has a resonant frequency, and
the array has a resonance frequency at or near the working frequency,
the unit cells configured such that they magnetically couple with one another,
the array producing, in the signals emitted by the specimen and measured by the MRI machine, a signal-to-noise ratio of at least 50.

US Pat. No. 10,282,833

GATE-LEVEL MAPPING OF INTEGRATED CIRCUITS USING MULTI-SPECTRAL IMAGING

Trustees of Boston Univer...

1. A method of optical verification testing of a portion of an integrated circuit, comprising:(a) obtaining one or more images of the portion of the integrated circuit by, for each image:
(i) illuminating the integrated circuit with excitation light, wherein the excitation light corresponds to a respective specific optical excitation of a predefined spectrum of optical excitations; and
(ii) detecting scattered light from the integrated circuit in response to the specific optical excitation; and
(b) for each of a plurality of sub-regions of the images, mapping the respective sub-region to at least one of (i) a specific sub-unit of a predefined set of sub-units of the integrated circuit and (ii) a null result, based on an intensity of one or more pixels within the sub-regions of the one or more images, wherein for each image, the intensity of the pixels corresponds to an intensity of detected scattered light from a corresponding region of the portion of the integrated circuit in response to the respective specific optical excitation, thereby creating a representation of a detected layout of the integrated circuit as an arrangement of the sub-units.

US Pat. No. 10,258,600

ARYL HYDROCARBON RECEPTOR (AHR) MODIFIERS AS NOVEL CANCER THERAPEUTICS

Trustees of Boston Univer...

1. A pharmaceutical composition comprising a compound of Formula (Ia):
wherein:
X? is alkyl, aryl or a substituted amino;
n is 1;
R2 is a substituted heteroaryl,
R3, R4, R5 and R6 are H,
or a pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable carrier, excipient or stabilizer, and wherein the pharmaceutical composition is formulated as a capsule, pill, caplet or tablet.
US Pat. No. 10,632,140

METHODS RELATING TO LUNG CANCER

TRUSTEES OF BOSTON UNIVER...

1. A method comprising:detecting the level of expression of miR-146a 5p
in a nasal epithelial sample obtained from a subject.

US Pat. No. 10,617,759

LIGHT-STIMULATED RELEASE OF CARGO FROM OLIGONUCLEOTIDES

Trustees of Boston Univer...

1. An oligonucleotide conjugate of the formula:wherein Oligo is an oligonucleotide of 2-1000 nucleotides in length, Ai is the residue of a conjugation reaction, A2 is an amine reactive leaving group or —NHX, L is an optional linker, Y is H or C1-10 alkyl, and X is a cargo moiety.

US Pat. No. 10,557,134

PROTECTION OF BARCODES DURING DNA AMPLIFICATION USING MOLECULAR HAIRPINS

TRUSTEES OF BOSTON UNIVER...

1. A method of amplifying a target nucleic acid in a sample comprising:a. contacting a sample comprising a target nucleic acid with a target-specific hairpin barcode forward primer and a target-specific reverse primer,
wherein the hairpin barcode forward primer comprises, in a 5? to 3? direction: a 5? stem sequence, an adaptor sequence, a barcode sequence, a 3? stem sequence, and a 3? target-specific sequence, wherein the 5? stem sequence and the 3? stem sequence each comprise sequence complementary to each other and the complementary sequences hybridize to each other under a closed annealing temperature and do not hybridize to each other at an open annealing temperature;
b. amplifying the target nucleic acid by performing 2-5 cycles of PCR pre-amplification on the target nucleic acid, wherein the 2-5 cycles of PCR pre-amplification have an annealing temperature less than or equal to the closed annealing temperature of the hairpin barcode forward primer, to generate a plurality of pre-amplification target nucleic acids;
c. contacting the plurality of pre-amplification target nucleic acids with an adaptor-specific forward primer and an adaptor-specific reverse primer; and
d. amplifying the pre-amplification target nucleic acid by performing at least 10 cycles of PCR amplification on the pre-amplification target nucleic acids, wherein at least 3 of the at least 10 cycles of PCR-based amplification have an annealing temperature greater than or equal to the open annealing temperature of the hairpin barcode forward primer, to generate a plurality of target nucleic acid amplicons, wherein the target nucleic acid amplicons comprise the adaptor sequence and the barcode sequence.

US Pat. No. 10,553,199

LOW-DIMENSIONAL REAL-TIME CONCATENATIVE SPEECH SYNTHESIZER

Trustees of Boston Univer...

1. A method of operating a computerized device to provide real-time synthesis of speech based on user input, comprising:presenting a graphical user interface having a low-dimensional representation of a multi-dimensional phoneme space, a first dimension representing degree of vocal tract constriction and voicing, a second dimension representing location in a vocal tract;
receiving user input via the interface and translating received user input into a sequence of phonemes; and
rendering the sequence of phonemes on an audio output device.

US Pat. No. 10,536,775

AUDITORY SIGNAL PROCESSOR USING SPIKING NEURAL NETWORK AND STIMULUS RECONSTRUCTION WITH TOP-DOWN ATTENTION CONTROL

Trustees of Boston Univer...

1. An auditory signal processor, comprising:a filter bank configured and operative to generate a plurality of frequency components of a source audio signal;
a spatial localization network configured and operative in response to the frequency components to generate a plurality of spike trains for respective spatially separated components of the source audio signal;
a cortical network configured and operative in response to the spike trains to generate a resultant spike train for selected spatially separated components of the source audio signal; and
a stimulus reconstruction circuit configured and operative to process the resultant spike train to generate a reconstructed audio signal for a target component of the source audio signal,
wherein (1) the cortical network incorporates top-down attentional inhibitory modulation of respective spatial channels to produce the resultant spike train for the selected spatially separate components of the source audio signal, and (2) the stimulus reconstruction circuit employs convolution of a reconstruction kernel with the resultant spike train to generate the reconstructed audio signal.
US Pat. No. 10,428,043

GREEN OXIDATION CATALYTIC SYSTEM

TRUSTEES OF BOSTON UNIVER...

1. A reaction mixture comprisingan oxidation catalyst comprising a metal ion complexed with an ?-keto acid and a tridentate N,N,O-ligand;
a solvent, wherein the solvent is in contact with the oxidation catalyst; and
a substrate dissolved in the solvent, wherein the solvent and the substrate are different; and wherein the solvent is a polar or polar aprotic solvent.
US Pat. No. 10,314,855

METHODS RELATING TO LUNG CANCER

TRUSTEES OF BOSTON UNIVER...

1. A method of treating lung cancer in a subject in need thereof, the method comprisingadministering a treatment for lung cancer to a subject determined to have a level of expression of at least 1 miRNAs selected from the group consisting of:
miR-146a-5p, miR-324-5p, miR-223-3p, miR-223-5p; miR-450b-5p, miR-221-3p-miR-505-3p, and miR-582-5p;
in a bronchial brushing or nose epithelial sample obtained from the subject which is decreased relative to a reference level,
wherein the treatment is resection, lobesctomy, pneumonectomy, radiation therapy, stereotactic body radiotherapy, chemotherapy, or immunotherapy.

US Pat. No. 10,266,951

METHOD AND APPARATUS FOR PRODUCING SOLAR GRADE SILICON USING A SOM ELECTROLYSIS PROCESS

TRUSTEES OF BOSTON UNIVER...

1. A method of manufacturing silicon via a solid oxide membrane electrolysis process, comprising:providing a first crucible defining a cavity;
providing a flux within said cavity of said first crucible, said flux comprising silicon oxide in solution;
providing a cathode disposed in said cavity of said first crucible in electrical contact with said flux, said cathode comprising a silicon-absorbing portion within a second crucible disposed inside said first crucible containing said flux, said silicon-absorbing portion being in fluid communication with said flux, said silicon-absorbing portion comprising a metal;
providing an anode disposed in said cavity of said first crucible and spaced apart from said cathode and being in electrical contact with said flux, said anode comprising a solid oxide membrane around at least a portion of said anode;
heating said flux and said silicon-absorbing portion to an operating temperature of said solid oxide membrane electrolysis process;
generating an electrical potential between said cathode and said anode sufficient to dissociate the silicon oxide and reduce silicon at said operating temperature of said solid oxide membrane electrolysis process, said operating temperature being sufficient to form a liquid solution of said silicon and said metal; and
cooling said silicon-absorbing portion to a precipitation temperature that is below said operating temperature and at which said silicon separates out of said silicon-absorbing portion and precipitates in solid form into said second crucible while the metal of the silicon-absorbing portion remains a liquid,
wherein said silicon-absorbing portion preferentially absorbs silicon relative to a remainder of said flux at said operating temperature, and said silicon-absorbing portion is a liquid at said operating temperature, and
wherein said solid oxide membrane is permeable to oxygen.

US Pat. No. 10,214,763

METHOD AND DEVICE FOR ANTIBIOTIC SUSCEPTIBILITY TESTING BASED ON FLUCTUATIONS OF ELECTRICAL RESISTANCE IN A MICROCHANNEL

TRUSTEES OF BOSTON UNIVER...

1. A method for detecting live bacteria in a microchannel comprisinga) providing a constant current or constant voltage through the microchannel wherein the microchannel does not contain any bacteria and measuring baseline voltage or current fluctuations through the microchannel to determine a baseline voltage or current fluctuation signal;
b) providing a constant current or constant voltage through the microchannel wherein the microchannel contains at least one bacterium and measuring voltage or current fluctuations through the microchannel to determine a first voltage or current fluctuation signal; and
c) determining that the at least one bacterium is alive if the first voltage or current fluctuation signal is greater than the baseline voltage or current fluctuation signal by a predefined threshold amount.

US Pat. No. 9,621,268

OPTICAL ORTHOGONAL FREQUENCY DIVISION MULTIPLEXING (O-OFDM) SYSTEM WITH PULSE-WIDTH MODULATION (PWM) DIMMING

Trustees of Boston Univer...

1. An optical orthogonal frequency division multiplexing (O-OFDM) system with pulse-width modulation (PWM) dimming, the system
comprising:
a driver responsive to one or more predetermined dimming set points configured to generate PWM signals having a predetermined
duty cycle and configured to supply current to one or more light emitting diodes (LEDs);

an O-OFDM generator responsive to the one or more predetermined dimming set points and digital data configured to generate
digital inverted O-OFDM signals during on-states of the PWM signals and non-inverted O-OFDM signals during off-states of the
PWM signals according to the predetermined duty cycle and convert the digital inverted O-OFDM signals and the digital non-inverted
O-OFDM signals to analog output O-OFDM signals; and

a combiner circuit responsive to the current from the driver and the analog output O-OFDM signals configured such that the
analog output O-OFDM signals modulate the current to the one or more LEDs to provide a high capacity visible light communication
link.

US Pat. No. 10,585,042

SYSTEMS AND METHODS FOR IMAGING MICROWELL PLATE SAMPLES

TRUSTEES OF BOSTON UNIVER...

1. A system for imaging one or more samples, the system comprising:a microwell plate including a plurality wells arranged in a plurality of rows, each of the plurality of wells having an upper opening and an opposing transparent lower surface, each of the plurality of wells being configured to store a sample therein;
a sensor array including a plurality of sensors, the sensor array being moveable relative to the microwell plate along a first axis between a first position and a second position, each of the plurality of sensors being positioned within a corresponding well at a predetermined depth for at least one of the plurality of rows responsive to the sensor array being in the second position;
an objective;
an imaging device; and
one or more linear translation stages configured to move the microwell plate relative to the objective along (i) a second axis, (ii) a third axis, or (iii) both (i) and (ii) to allow the imaging device to obtain image data reproducible as one or more images of each of the plurality of sensors.
US Pat. No. 10,570,454

METHODS OF IDENTIFYING INDIVIDUALS AT INCREASED RISK OF LUNG CANCER

Trustees of Boston Univer...

1. A method of processing a sample, comprising obtaining an airway epithelial sample by airway epithelial brushing comprising a cytologically normal airway epithelial cell and measuring the phosphorylation of IGF1R with an antibody in the cytologically normal airway epithelial cell.

US Pat. No. 10,488,328

POLARIZATION ENHANCED INTERFEROMETRIC IMAGING

TRUSTEES OF BOSTON UNIVER...

1. An interferometric reflectance imaging system comprising:a target including a substrate having a first reflecting surface and a transparent layer on the first reflecting surface forming a second reflective surface separated from the first reflecting surface by a thickness of the transparent layer;
a light source configured to produce illumination light along an illumination path toward the target, the illumination light being polarized according to a first polarization configuration;
wherein the first reflecting surface and the second reflecting surface of the target is positioned to receive the illumination light and reflect the illumination light along a collection path toward an imaging sensor and result in signal interference in the reflected illumination light; and
a filter positioned in the collection path to filter light polarized according to the first polarization configuration whereby substantially all of the reflected illumination light reflected by the first reflecting surface and the second reflecting surface is not received by the imaging sensor.
US Pat. No. 10,386,368

ISOLATION OF HUMAN LUNG PROGENITORS DERIVED FROM PLURIPOTENT STEM CELLS

TRUSTEES OF BOSTON UNIVER...

1. A method for isolating a lung progenitor cell, the method comprising:(a) contacting a population of cells comprising lung primordial progenitor cells with an antibody that recognizes CD47 and a second antibody that recognizes CD26 to determine the level of expression of CD47 and CD26, and
(b) isolating at least one cell with a cell surface phenotype comprising a CD47 expression level that is at least 20% greater than the CD47 expression level in a control cell and comprising a CD26 expression level that is at least 20% lower than the CD26 expression level in a control cell,
wherein the control cell is a cell that is not committed to the lung lineage,
thereby isolating a CD47hi/CD26lo lung progenitor cell from the population of cells comprising lung primordial progenitor cells.

US Pat. No. 10,314,810

ARYL HYDROCARBON RECEPTOR (AHR) MODIFIERS AS NOVEL CANCER THERAPEUTICS

Trustees of Boston Univer...

1. A pharmaceutical composition comprising an aryl hydrocarbon receptor (AhR) modulator according to Formula (Ia) and a pharmaceutically acceptable excipient, carrier or stabilizer:
wherein:
X? is H, unsubstituted alkyl, aminosulfonyl, acyl, aryl, or heteroaryl, where each of aminosulfonyl, acyl, aryl, or heteroaryl may be optionally substituted;
n is 0-6;
R2 is H, alkyl, acyl, heteroaryl, arylalkyl, cycloalkyl, heteroarylalkyl, heterocyclyl, or haloalkyl, each of which may be optionally substituted;
R3, R4, R5 and R6 are independently H, alkyl, acyl, halo, aryl, or heteroaryl, each of which may be optionally substituted; or
a steroisomer or
pharmaceutically acceptable salt thereof; and
wherein the pharmaceutical composition is formulated as a capsule, pill, caplet or tablet.

US Pat. No. 10,734,782

ULTRASHORT PULSE FIBER LASER EMPLOYING RAMAN SCATTERING IN HIGHER ORDER MODE FIBERS

Trustees of Boston Univer...

1. A fiber laser, comprising:a higher-order-mode (HOM) fiber having a step index and a guidance diameter together defining respective wavelength-dependent anomalous dispersion characteristics and effective areas greater than 100 square micrometers for corresponding higher-order modes of optical signal propagation in the HOM fiber, the higher-order modes including a predetermined higher-order mode with corresponding anomalous dispersion characteristic and effective area defining a first wavelength and first power of a pulse optical signal for conversion to a second wavelength and second power by soliton self-frequency shifting in the HOM fiber, the second wavelength and second power being related to the first wavelength and first power by the anomalous dispersion characteristic and effective area for the predetermined higher-order mode; and
a source subsystem coupled to the HOM fiber to establish the pulse optical signal propagating in the HOM fiber in the predetermined higher-order mode;
wherein the pulse optical signal is a soliton having an energy Esol proportional to a dispersion value D and effective area Aeff for the predetermined higher-order mode as well as to a difference ?? between the first and second wavelengths, and wherein the pulse optical signal has a peak power of one kilowatt or greater.
US Pat. No. 10,633,712

ASSAYS AND METHODS RELATING TO THE TREATMENT OF MELANOMA

TRUSTEES OF BOSTON UNIVER...

1. A method of treatment for melanoma, the method comprising:a) surgically removing the melanoma and administering adjuvant therapy and follow-up monitoring to a subject determined to have a level of neurophilin-2 (NRP-2) mRNA: melan-A (MART) mRNA in a sample obtained from the subject which is increased relative to a reference level;
b) surgically removing the melanoma and not administering adjuvant therapy to a subject determined to have a level of neurophilin-2 (NRP-2) mRNA: melan-A (MART) mRNA in a sample obtained from the subject which is not increased relative to a reference level.

US Pat. No. 10,504,614

SYSTEMS AND METHODS FOR DETERMINING AN UNKNOWN CHARACTERISTIC OF A SAMPLE

RUTGERS, THE STATE UNIVER...

1. A method for determining a number of contributors to a DNA mixture, the method comprising:analyzing each of a plurality of calibration samples at a plurality of concentrations to generate a calibration sample profile corresponding to each of the plurality of calibration samples wherein each calibration sample profile comprises a plurality of allele peaks, and wherein each of the calibration samples is a biological sample comprising DNA that is obtained from a single contributor;
generating, by a processor, for each of the plurality of calibration samples, calibration data from the corresponding calibration sample profile by modeling heights of the plurality of allele peaks, wherein the calibration data models one or more variables as a function of input DNA mass in the corresponding calibration sample;
analyzing a test sample to generate a test sample profile, wherein the test sample is a biological sample comprising a DNA mixture from one or more contributors, and wherein the number of contributors is unknown;
analyzing, by the processor, the calibration data and the test sample profile to generate a probability distribution of a number of contributors to the test sample for estimating the number of contributors to the DNA sample; and
using the estimated number of contributors to determine whether an individual should be included as a contributor to the DNA mixture during forensic analysis, wherein:
the plurality of calibration sample and the test sample are analyzed using the same laboratory device under the same test conditions.
US Pat. No. 10,465,187

INTEGRATED SYSTEM FOR PROGRAMMABLE DNA METHYLATION

Trustees of Boston Univer...

1. An engineered DNA methylation system comprising:a. a reporter module comprising a nucleic acid sequence comprising one or more DNA binding domain target sites, one or more GATC nucleic acid sequences, a promoter nucleic acid sequence, and a nucleic acid sequence encoding a reporter molecule;
b. a writer module comprising a promoter sequence operably linked to a nucleic acid sequence encoding a writer fusion protein comprising: a DNA binding protein or domain thereof and a DNA adenine methyltransferase comprising the amino acid sequence of any one of SEQ ID NOs: 12-31;
c. a reader-effector module comprising a promoter sequence operably linked to a nucleic acid sequence encoding a reader-effector fusion protein comprising: a methyl-adenine DNA binding domain of DpnI endonuclease and one or more transcriptional effector domains, wherein the one or more transcriptional effector domains are repressive transcriptional domains or activating transcriptional domains; and
d. a reader-writer module comprising a promoter sequence operably linked to a nucleic acid sequence encoding a reader-writer fusion protein comprising: a DNA adenine methyltransferase comprising the amino acid sequence of any one of SEQ ID NOs: 12-31 and a methyl-adenine DNA binding domain of DpnI endonuclease.

US Pat. No. 10,705,138

OPTICAL ANTENNAS FOR ADVANCED INTEGRATED CIRCUIT TESTING

Trustees of Boston Univer...

1. A semiconductor device, comprising:functional circuit elements formed by registered and interconnected segments of semiconductor material and metal at respective layers of the device; and
optical antennas formed as optical test points at selected test locations for the functional circuit elements on the device, the optical antennas converting between radiated optical energy to or from a test system and corresponding localized optical energy at the test locations, the optical antennas being formed from metal segments on the same metal layers used for signal interconnections within and between the functional circuit elements,
wherein the metal includes first portions and second portions, the first portions including metal having electrical functionality in the functional circuit elements, the second portions including (i) first metal segments lacking electrical functionality and providing etch and process uniformity, and (ii) second metal segments forming the optical antennas.

US Pat. No. 10,646,451

GM3 FUNCTIONALIZED NANOPARTICLES

TRUSTEES OF BOSTON UNIVER...

1. A nanoparticle comprising:a) a biodegradable core having a largest diameter between 50-90 nm;
b) a coating layer encasing the biodegradable core, wherein the biodegradable core comprises a material selected from the group consisting of silica, mesoporous silica, polystyrene, titania, polyhydroxyalkanoates, polylactic acid (PLA), polybutylene succinate (PBS), polycaprolactone (PCL), polyanhydrides, polyvinyl alcohol, and cellulose esters; and
c) a ganglioside GM3-containing mixed lipid layer comprising of dipalmitoylphosphatidylcholine (DPPC), cholesterol, phosphatidylserine (PS), and aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer (GM3); wherein the ganglioside GM3-mixed lipid layer is exterior of the coating layer and is integrated into the coating layer, and wherein the nanoparticles have an overall particle size between 60-100 nm.

US Pat. No. 10,617,794

MACROINITIATORS FOR HYDROPHILIC COATINGS ON LATEX AND APPLICATIONS THEREOF

Trustees of Boston Univer...

1. A composition comprising: a latex article having at least one layer of a hydrophilic coating, wherein the hydrophilic coating comprises a co-polymer network comprising a macroinitiating co-polymer and a hydrophilic polymer on the surface of the latex article, and wherein the macroinitiating co-polymer structure: (a) is selected from the group consisting of:
or (b) comprises a structure selected from the group consisting of:

wherein, in Formulas A-G, n and m are integers that represent the number of randomized repeat unit in which n can range from 10 to 5000 and the proportion of the monomer with the m subscript can range from 1% to 50% w/w of the monomer with the n subscript.

US Pat. No. 10,275,656

LARGE SCALE VIDEO SEARCH USING QUERIES THAT DEFINE RELATIONSHIPS BETWEEN OBJECTS

TRUSTEES OF BOSTON UNIVER...

1. A relationship-based video server system, programmed to provide a platform for large scale video search based on relationships between objects in video segments, the platform executing search based on probabilistically discriminative objects and relationships, wherein the server system is configured to run processes that:for each video segment received for storage in a video database,
analyze image data in the video segment to (1) recognize objects that are represented in the video segment and (2) identify relationships between the objects,
determine, based on probabilities of occurrence for the recognized objects and identified relationships, at least one of (1) the most discriminative object or (2) the most discriminative relationship in the video segment,
configure, based on at least one of the most discriminative object or the most discriminative relationship, a data structure that includes the recognized objects and identified relationships of the video segment;
store the data structure in the video database;
receive a video search query defining relationships between a plurality of objects;
determine, based on probabilities of occurrence for the objects and relationships of the video search query, at least one of the most discriminative object or the most discriminative relationship of the video search query;
identify, based on at least one of the most discriminative object or the most discriminative relationship of the video search query, a subset of the data structures to search for video segments;
determine, for each video segment represented in the subset of the data structures, a score based on similarity between the objects and the relationships in the video search query and the objects and the relationships associated with the video segment; and
display representations of video segments with the highest scores.

US Pat. No. 10,219,581

METHOD AND APPARATUS TO ASSIST FOOT MOTION ABOUT THE PRONATION AXIS

Trustees of Boston Univer...

1. An apparatus for assisting movement of a foot having a pronation axis, the apparatus comprising:a plate configured to interact with the foot, the plate having a top surface and a bottom surface, the plate having a forefoot region and a rearfoot region, the forefoot region having a forefoot lateral region and a forefoot medial region, the rearfoot region having a rearfoot lateral region and a rearfoot medial region, the plate being twisted about a plate axis that is configured to approximate the pronation axis of the foot when at rest,
the forefoot lateral region, the forefoot medial region, and the rearfoot lateral region each having at least one point on the bottom surface that together share a common plane when the plate is at rest, the rearfoot medial region having at least one point on the bottom surface that is spaced from the common plane when at rest,
the forefoot region being transversely concave on the bottom surface and having a first radius of curvature when at rest, the rearfoot region being transversely concave on the bottom surface and having a second radius of curvature when at rest, the first radius of curvature being greater than the second radius of curvature,
the plate being biased to resist a pronatory torque applied by the foot during pronation and configured to twist, in response to the pronatory torque, about the plate axis, the plate further configured to apply a non-linear force substantially about the plate axis during foot pronation.
US Pat. No. 10,533,225

METHODS AND SYSTEMS FOR MONITORING, DIAGNOSING, AND TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE

TRUSTEES OF BOSTON UNIVER...

1. A method of detecting respiratory tract epithelium gene expression, comprising:(a) obtaining a respiratory tract epithelium sample from a human subject; and
(b) detecting expression in the sample of each gene of a gene set, wherein the gene set consists of ABCA12, CFB, and FOS.

US Pat. No. 10,505,629

VISIBLE-LIGHT COMMUNICATIONS RECEIVER

Trustees of Boston Univer...

1. An optical wireless communications receiver, comprising:a set of photodetectors and associated signal processing circuitry collectively operative to receive and process communications signals to generate one or more streams of receive data;
a spatial light modulator and associated SLM controller, the spatial light modulator being configured to receive a plurality of incident optical communications signals from remote optical transmitters and to selectively direct the received optical communications signals to the photodetectors to realize an SLM pattern according to SLM control signals from the SLM controller; and
a system controller operative to control how the SLM changes the SLM pattern and communicate a description thereof to the SLM controller for use in generating the SLM control signals.

US Pat. No. 10,677,542

ENHANCED THERMAL TRANSPORT ACROSS INTERFACES

TRUSTEES OF BOSTON UNIVER...

1. A method for creating an interface between a first surface characterized by a first thermal conductivity and a substrate, the substrate characterized by a second thermal conductivity exceeding the thermal conductivity of the first surface, the method comprising:a. providing the first surface characterized by a first thermal conductivity and the substrate, the substrate characterized by a second thermal conductivity exceeding the thermal conductivity of the first surface;
b. increasing the surface area of at least one of the first surface and the substrate by at least one percent by subtractively nanostructuring at least one of the first surface and the substrate to create a nanostructured surface with features characterized by an aspect ratio of at least 1.1:1 above the respective first surface and substrate;
c. functionalizing each nanostructured surface; and
d. bonding the first surface to the substrate, wherein bonding includes bringing the first surface and the substrate into proximity with one another, and flowing a surface layer at an interface between the surface and the substrate, whether by heating, pressure or otherwise.

US Pat. No. 10,613,076

OPTOELECTRONIC CONTROL OF SOLID-STATE NANOPORES

THE TRUSTEES OF BOSTON UN...

1. A method for characterizing an analyte comprising:providing a solid-state membrane comprising a nanopore submerged in a saline solution;
optoelectronically modifying a surface of the nanopore, while the solid-state membrane is submerged in the saline solution, to cause a measurable change in the nanopore ionic conductance not induced by a thermal effect;
applying an electric field across the solid-state membrane to generate an ion current through the nanopore and to translocate the analyte through the nanopore; and
detecting variations in the ion current and/or light emission from the analyte, wherein the variations in current and/or in the light emission correspond to interactions between the analyte and nanopore surface.

US Pat. No. 10,451,808

MEMS DEVICES FOR SMART LIGHTING APPLICATIONS

TRUSTEES OF BOSTON UNIVER...

1. A device comprising:a base substrate;
a platform suspended over the base substrate;
a plurality of support elements supporting the platform over the base substrate, wherein each support element has a first end and a second end, wherein the first end of each support element is mounted on the base substrate and connected to an electrical source, and wherein the second end of each support element is suspended over the base substrate, the plurality of support elements being configured to cause the platform to move relative to the base substrate; and
a micromirror including a first portion directly attached to the platform such that the first portion cannot move relative to the platform and a second portion that is not attached to the platform such that the second portion can move relative to the platform, the micromirror including a material that is configured to enable the second portion of the micromirror to move relative to the platform responsive to an input.

US Pat. No. 10,378,954

AZIMUTHALLY-MODULATED APERIODIC PHASE ARRAYS FOR ENGINEERED SPECTRAL SEPARATION

TRUSTEES OF BOSTON UNIVER...

1. An optical mask comprising:a substrate layer;
an opaque layer; and
a functional layer,
wherein the functional layer in conjunction with the opaque layer is configured to impart orbital angular momentum and linear momentum on incoming electromagnetic radiation.

US Pat. No. 10,683,316

SYNTHETIC CATALASE/SUPEROXIDE DISMUTASE MIMETICS AND METHODS FOR TREATING VIRAL INFECTIONS

The United States of Amer...

1. A method of treating pandemic influenza viral infection in a subject, the method comprising:identifying a subject as having a pandemic influenza viral infection that is in need of treatment for at least one of adult respiratory distress syndrome (ARDS), severe necrotizing bronchitis, severe bronchiolitis, severe alveolitis, severe edema, severe pulmonary hemorrhage, or combinations thereof; and
administering to the subject an effective amount of a compound, wherein the compound is:

or a pharmaceutically acceptable salt, ester or hydrate thereof, wherein the compound is effective at decreasing or reducing at least one symptom of at least one of ARDS, severe necrotizing bronchitis, the severe bronchiolitis, the severe alveolitis, the severe edema, the severe pulmonary hemorrhage, or combinations thereof.

US Pat. No. 10,678,037

REVERBERATION MICROSCOPY SYSTEMS AND METHODS

Trustees of Boston Univer...

1. A method for obtaining one or more images of a tissue sample using a microscope, the method comprising:dividing, using a reverberation cavity, a first one of a plurality of laser pulses into a plurality of sequential sub-pulses, each of the plurality of sequential sub-pulses having a power that is less than a previous one of the plurality of sequential sub-pulses;
directing, using the one or more lenses of the microscope, the plurality of sequential sub-pulses onto a portion of the tissue sample to generate a plurality of fluorescence signals, each of the plurality of fluorescence signals being associated with a different depth within the tissue sample;
detecting the plurality of fluorescence signals from the tissue sample; and
generating one or more images of at least a portion of the tissue sample based at least in part on the plurality of fluorescence signals.
US Pat. No. 10,646,614

DISSOLVABLE HYDROGEL COMPOSITIONS FOR WOUND MANAGEMENT AND METHODS OF USE

TRUSTEES OF BOSTON UNIVER...

1. A dissolvable hydrogel composition comprising: an adhesive hydrogel layer comprising a first water-soluble linear, branched and/or dendritic crosslinkable polymer and a second water-soluble linear, branched and/or dendritic crosslinkable polymer held together by covalent bonds formed between the first crosslinkable polymer and the second crosslinkable polymer, wherein the second crosslinkable polymer comprises at least two thioester linkages within its backbone.

US Pat. No. 10,925,975

ACIDIC NANOPARTICLES FOR RESTORATION OF AUTOPHAGY

THE REGENTS OF THE UNIVER...

1. An acid-releasing fluorinated polyester nanoparticle (acNP) comprising:(i) a polyester and (ii) a tetrafluorosuccinic acid (TFSA),wherein the nanoparticle releases an acid when exposed to an environment having a pH of about pH 6.0.

US Pat. No. 10,768,165

SYSTEMS AND METHODS FOR MEASURING WATER AND LIPID CONTENT IN TISSUE SAMPLES

TRUSTEES OF BOSTON UNIVER...

1. A method for measuring blood lipid content in a blood vessel in a tissue sample, the method comprising:generating, using a light source and a spatial modulation device, a first plurality of patterns at a first spatial frequency on a plane of a tissue sample of a subject and a second plurality of patterns at a second spatial frequency on the plane of the tissue sample for a first wavelength of light from a plurality of sequential wavelengths of light, the light source being configured to emit the plurality of sequential wavelengths of light within a predetermined range of wavelengths;
obtaining, using an imaging device, (i) first image data reproducible as images of the first plurality of patterns at the first spatial frequency for the first wavelength of light and (ii) second image data reproducible as images of the second plurality of patterns at the second spatial frequency for the first wavelength of light;
generating, using a controller, a first demodulated image for the first wavelength of light based on the first image data;
determining, using the controller, a first diffuse reflectance value for each of a plurality of locations on the plane of the tissue sample at the first wavelength of light based on the first demodulated image;
generating, using the controller, a second demodulated image for the first wavelength of light based on the second image data;
determining, using the controller, a second diffuse reflectance value for each of the plurality of locations on the plane on the tissue sample for the first wavelength of light based on the second demodulated image;
determining, using the controller, based on the first diffuse reflectance value and the second diffuse reflectance value, (i) a first optical property and (ii) a second optical property for each of the plurality of locations on the plane of the tissue sample for the first wavelength of light;
determining a molar concentration for a plurality of chromophores based on the first optical property and the second optical property, the plurality of chromophores including a lipid, oxy-hemoglobin, and de-oxy hemoglobin;
identifying a blood vessel in the tissue sample based at least in part on the determined first optical property, the determined second optical property, or both at each of the plurality of locations on the plane of the tissue sample; and
determining a blood lipid content in the identified blood vessel in the tissue sample based on the molar concentration of the plurality of chromophores.
US Pat. No. 10,660,911

PROTON-MOTIVE FORCE STIMULATION TO POTENTIATE AMINOGLYCOSIDE ANTIBIOTICS AGAINST PERSISTENT BACTERIA

TRUSTEES OF BOSTON UNIVER...

1. A method for treating a chronic or persisting bacterial infection, the method comprising administering to a subject having or at risk for a chronic or persisting bacterial infection an effective amount of an aminoglycoside antibiotic selected from the group consisting of: kanamycin and streptomycin and an effective amount of pyruvate as an adjuvant.

US Pat. No. 10,622,628

ELECTRODE COMPRISING HEAVILY-DOPED CERIA

TRUSTEES OF BOSTON UNIVER...

1. An electrode comprising:a functional layer comprising an Ln2MO4 phase, where Ln is at least one lanthanide optionally doped with a metal and M is at least one 3d transition metal;
the functional layer further comprising a ceria phase comprising doped ceria having a general formula Ce(1-x-y)AxByO2, where A is at least one rare earth dopant, B is at least one alkaline earth dopant, x is greater than 0.2, y is in a range of 0 to 0.2, and x+y is greater than 0.4 and no greater than a solubility limit of ceria.
US Pat. No. 10,526,582

MULTI-LAYERED CELL CONSTRUCTS AND METHODS OF USE AND PRODUCTION USING ENZYMATICALLY DEGRADABLE NATURAL POLYMERS

TRUSTEES OF BOSTON UNIVER...

1. A method of making a multi-layered cell construct comprising the steps of, in the order of:a. contacting a second cell layer with a receiving cell layer, wherein the second cell layer is present on a second substrate, and the receiving cell layer comprises at least one cell layer and is present on a receiving substrate, and wherein the receiving substrate has cell-adhesive properties and can be digested by a first enzyme, and the second substrate can be digested by a second enzyme, wherein the receiving substrate and second substrate comprise different enzyme digestible polymers and the first enzyme is different from the second enzyme, then
b. applying pressure to the second substrate and the receiving substrate, and then
c. applying a second enzyme to digest the second substrate thereby removing the second substrate, wherein after digestion of the second substrate, the receiving substrate comprises multiple cell layers comprising the at least one receiving cell layer and the second cell layer and wherein there is no substrate between the cell layers of the multiple cell layers, then
d. after the digestion of the second substrate in step (c), repeating steps (a)-(c) in order at least once, wherein the second cell layer of the multiple cell layers present on the receiving substrate in step (c) is used as the receiving cell layer tar step (a), and then
e. applying a first enzyme to digest the receiving substrate to form the multi-layered cell construct.
US Pat. No. 10,449,221

DIFFERENTIATION OF STEM CELLS INTO THYROID TISSUE

TRUSTEES OF BOSTON UNIVER...

1. An ex vivo or in vitro method for producing a mature thyroid follicular epithelial cell comprising:a) contacting an endodermal cell with a thyroid lineage culture medium to differentiate the endodermal cell into the thyroid lineage without exogenously delivered nucleic acid sequences resulting in the forced over-expression of the Nkx2-1 protein and the Pax8 protein in the endodermal cell, thereby producing a Nkx2.1+ and Pax8+ thyroid progenitor cell, wherein the thyroid lineage culture medium comprises:
i) bone morphogenetic protein 4 (BMP4), and
ii) fibroblast growth factor 2 (basic) (FGF2), and
wherein the thyroid lineage culture medium does not contain:
iii) Wingless-Type MMTV Integration Site Family protein, member 3A, (Wnt3A),
iv) fibroblast Growth Factor 10 ((FGF10),
v) keratinocyte Growth Factor (KGF), and
vi) epidermal growth factor (EGF),
b) isolating and culturing the Nkx2-1+/Pax8+ thyroid progenitor cell of step (a) in a differentiation medium comprising fibroblast growth factor 2 (basic) (FGF2) for a time sufficient to permit differentiation of the Nkx2-1+/Pax8+ thyroid progenitor cell along the thyroid lineage; and
c) culturing the further differentiated cell produced in step (b) in a maturation medium comprising dexamethasone and thyroid stimulating hormone (TSH), under conditions and for a time sufficient to produce a Nkx2-1+/Pax8+ co-expressing cell that also expresses early and mature thyroid markers: thyroglobulin (Tg+), thyroid stimulating hormone receptor (Tsh+), sodium iodine symporter (Nis+), and thyroid peroxidase (Tpo+),
thereby producing a mature thyroid follicular epithelial cell.

US Pat. No. 10,361,343

ULTRAVIOLET LIGHT EMITTING DIODES

Trustees of Boston Univer...

1. A deep ultraviolet light-emitting diode comprising:a base layer including a p-type material forming a first side of the diode;
an active layer grown on the base layer, whereby radiative recombination of carriers in the active layer produces ultraviolet light in response to an applied electric field;
a light reflecting layer disposed between the base layer and the active layer, wherein the light reflecting layer reflects the ultraviolet light away from the base layer, and
an n-AlGaN layer grown on the active layer, wherein the n-AlGaN is on a second side of the diode which is opposite to the first side, and wherein the active layer is disposed between the base layer and the n-AlGaN layer and wherein the n-AlGaN layer includes a textured surface, whereby ultraviolet light is emitted from the textured surface.

US Pat. No. 10,928,315

MULTIPLEXED PHENOTYPING OF NANOVESICLES

TRUSTEES OF BOSTON UNIVER...

1. A method for quantifying and/or characterizing extracellular vesicles from a biological sample, the method comprising:(a) contacting a sensor of a single particle interferometric reflectance imaging sensor (SP-IRIS) system comprising an extracellular vesicle-specific probe with a biological sample comprising at least one extracellular vesicle, thereby capturing extracellular vesicle(s) on the sensor,
(b) contacting the sensor of the SP-IRIS system having the captured extracellular vesicle(s) with a secondary probe comprising a nanoparticle, and
(c) imaging the nanoparticle using the SP-IRIS system, thereby quantifying and/or characterizing extracellular vesicles from the biological sample.
US Pat. No. 10,858,443

SYNTHETIC NOTCH PROTEIN FOR MODULATING GENE EXPRESSION

TRUSTEES OF BOSTON UNIVER...

1. A synthetic Notch receptor protein comprising, from N-terminal to C-terminal and in covalent linkage, (i) a ligand binding domain (LBD), (ii) a scFV that binds to an at least one Notch NRR (Negative Regulatory Region), (iii) a Notch NRR bound by the scFV, (iv) a transmembrane domain, and (v) an intracellular domain.
US Pat. No. 10,614,353

BIOLOGICAL ANALOG-TO-DIGITAL AND DIGITAL-TO-ANALOG CONVERTERS

TRUSTEES OF BOSTON UNIVER...

1. A digital-to-analog biological converter switch, the digital-to-analog biological converter switch comprising at least two single invertase memory modules (SIMM), wherein each SIMM is an engineered nucleic acid construct comprising nucleic acid sequences in following order; an inducible promoter sequence (iP), a forward recombinase recognition site sequence (RRSfor), an inverted promoter sequence (Pinv), a recombinase gene sequence (RC), a reverse recombinase recognition site sequence (RRSrev), an inverted second inducible promoter sequence (iPinv, 2), and an output product sequence (OP), (iP-RRSfor-Pinv-RC-RRSrev-iPinv, 2-OP)n;wherein the recombinase gene sequence of each SIMM encodes a recombinase that recognizes the RRSfor and RRSrev of that SIMM; and wherein n?2.
US Pat. No. 10,590,392

GENERATION OF AIRWAY EPITHELIAL ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS

TRUSTEES OF BOSTON UNIVER...

1. A method for producing airway epithelial organoids comprising at least 70% airway epithelial NKX2-1+/SOX2+ cells, NKX2-1+/P63+ cells or NKX2-1+/P63+/K5 cells, the method consisting essentially of:(i) obtaining a population of NKX2-1 lung epithelial progenitors, wherein the population of NKX2-1 lung epithelial progenitors express makers NKX2-1, CD47 and CD26, wherein the expression of CD47 is at higher level as compared to the level of expression of CD26 (NKX2-1+, CD47hi and CD26low), wherein the NKX2-1+ lung epithelial progenitors are produced using a high wnt media, or in the presence of a Wnt activator that results high levels of Wnt signaling activity, and
(ii) culturing the population of NKX2-1 lung epithelial progenitors in a low-Wnt media that results in decreased Wnt signaling activity in NKX2-1 lung epithelial progenitors, wherein the NKX2-1 lung epithelial progenitors are cultured for a sufficient amount of time to direct their differentiation along a proximal epithelial differentiation pathway rather than along a distal pathway, to generate airway epithelial organoids comprising airway epithelial cells having proximal airway markers selected from any of NKX2-1+/SOX2+, NKX2-1+/P63+ or NKX2-1+/P63+/K5.

US Pat. No. 10,527,712

RAY-SURFACE POSITIONING SYSTEMS AND METHODS

TRUSTEES OF BOSTON UNIVER...

1. A method for estimating a position of a receiver within a three-dimensional coordinate system, the method comprising:targeting a laser beam onto the receiver, the laser beam being emitted from an optical source positioned at an origin of the three-dimensional coordinate system;
with the laser beam targeted on the receiver, identifying a first angle of the laser beam relative to a first axis of the three-dimensional coordinate system and a second angle of the laser beam relative to a second axis of the three-dimensional coordinate system;
based on the first angle of the laser beam, the second angle of the laser beam, and an isointense curve associated with the receiver and a transmitter, determining a predicted received signal strength from the transmitter at a plurality of points along the laser beam;
measuring, using the receiver, an actual received signal strength at the receiver associated with a transmission from the transmitter;
comparing the predicted received signal strength from the transmitter for the plurality of points along the laser beam with the measured actual received signal strength at the receiver;
determining that the predicted received signal strength associated with at least one of the plurality of points along the laser beam corresponds with the measured actual received signal strength at the receiver; and
responsive to determining that the predicted received signal strength corresponds with the measured actual received signal strength, determining a first predicted three-dimensional position within the three-dimensional coordinate system of the receiver relative to the optical source.

US Pat. No. 11,042,016

MULTI-Z CONFOCAL IMAGING SYSTEM

TRUSTEES OF BOSTON UNIVER...


1. A multi-Z confocal imaging system comprising:a LASER illumination source configured to direct a single monochromatic illumination beam through a microscope objective along a Z axis at a sample, and wherein the single monochromatic illumination beam under fills an aperture of the microscope objective and the microscope objective focuses the single monochromatic illumination beam into a monochromatic illumination line extending along the Z axis into a predefined target area of the sample; and
a scanning mechanism including at least one mirror configured to scan the monochromatic illumination line over the sample whereby a detection signal emanates from the sample through the microscope objective and the detection signal is formed into a detection beam directed toward a detection subsystem;
wherein the detection subsystem includes a first reflecting pinhole positioned at a predefined location with respect to the detection beam such that a first portion of the detection beam is captured by the first reflecting pinhole and is detected by a first optical detector and any remaining portion of the detection beam passes to a second reflecting pinhole positioned at a predefined location with respect to the first reflecting pinhole and a second portion of the detection beam is captured by the second reflecting pinhole and is detected by a second optical detector; and wherein the first optical detector outputs a first signal representative of an image from a first depth along the Z axis in the sample at the predefined target area at substantially the same time as the second optical detector outputs a second signal representative of an image from a second depth along the Z axis in the sample at the predefined target area that is different from the first depth along the Z axis in the sample.

US Pat. No. 10,996,383

DIFFRACTIVE AXILENSES AND USES THEREOF

TRUSTEES OF BOSTON UNIVER...

1. An optical element comprising:a substrate having a top surface and a bottom surface;
a pattern provided on the top, surface, the pattern including multiple phase discretization levels such that a thickness of the pattern is less than a design wavelength, the pattern having a spatial distribution of dielectric elements with engineered thicknesses and shapes that implement a phase transformation ?m(p, ?, r, f0, ?f, R, N) on a phase ?ax of an axilens according to the expression ?ax(r)+?m(p, ?, r, f0, ?f, R, N), where
p is the vector period of the modulation phase function, ? is the design wavelength, r=?x2+y2, f0 is the focal length, ?f is the focal depth, and R is the maximum radius of the axilens, and N is the number of phase discretization levels,wherein the pattern is configured to focus an incident radiation received at one of the top surface or the bottom surface of the substrate at one or more prescribed focal locations on a detection plane, wherein the one or more prescribed focal locations on the detection plane changes in proportion to a wavelength of the incident radiation, and wherein the detection plane is an achromatic focal plane when the incident radiation includes multiple wavelengths.
US Pat. No. 10,996,231

CERAMIDES FOR EVALUATING RISK OF CARDIOVASCULAR DISEASE

Washington University, S...

1. A method to determine a risk of cardiovascular disease (CVD) in a subject, the method comprising:providing or having been provided a biological sample from a subject having unknown CVD status;
extracting ceramide 24:0, and optionally ceramide 22:0 from the biological sample by protein precipitation in a solution comprising isopropanol and chloroform, resulting in an extracted sample;
injecting the extracted sample comprising a stable isotope internal standard into a liquid chromatography-mass spectrometer (LC-MS/MS) and measuring an amount of ceramide 24:0, and optionally ceramide 22:0 in the extracted sample;
wherein,
the extracted sample is separated by gradient LC comprising a mobile phase composition and a step gradient of the mobile phase composition over a period of about 5 min;
the mobile phase composition comprises solvent B comprising about 0.1% formic acid in isopropanol and, optionally, solvent A comprising about 0.1 formic acid in water; and
the step gradient comprises
(a) holding the mobile phase composition comprising about 65% solvent B and about 35% solvent A constant for about 0.5 min;
(b) changing the mobile phase composition comprising about 65% solvent B and about 35% solvent A to about 90% solvent B and about 10% solvent A over a step gradient time of about 1.5 min;
(c) changing the mobile phase composition comprising about 90% solvent B and about 10% solvent A to about 100% solvent B over the step gradient time of about 0.1 min;
(d) holding the mobile phase composition comprising about 100% solvent B constant for about 0.9 min;
(e) changing the mobile phase composition comprising about 100% solvent B to about 65% solvent B and about 35% solvent A over the step gradient time of about 0.1 min; and
(f) holding the mobile phase composition comprising about 65% solvent B and about 35% solvent A for about 1.9 min;
comparing the amount of ceramide 24:0 in the biological sample to a reference value of ceramide 24:0, and optionally comparing the amount of ceramide 22:0 in the biological sample to a reference value of ceramide 22:0; and
classifying the subject as at highest risk for CVD if the amount of ceramide 24:0 is less than the reference value of ceramide 24:0 of 1.97 ?g/ml, and optionally ceramide 22:0 is less than the reference value of ceramide 22:0 of 0.523 ?g/ml;
classifying the subject as at lower risk for CVD if the amount of ceramide 24:0 is less than the reference value of ceramide 24:0 of 2.45 ?g/ml, and optionally ceramide 22:0 is less than the reference value of ceramide 22:0 of 0.659 ?g/ml; or
classifying the subject as at least risk for CVD if the amount of ceramide 24:0 is greater than the reference value of ceramide 24:0 of 2.45 ?g/ml, and optionally ceramide 22:0 is greater than the reference value of ceramide 22:0 of 0.659 ?g/ml.

US Pat. No. 10,989,736

CANTILEVER-FREE SCANNING PROBE MICROSCOPY

TRUSTEES OF BOSTON UNIVER...

1. A system, comprising:a probe assembly, including
a rigid substrate,
a compliant layer provided on the rigid substrate,
one or more rigid probes coupled to at least a portion of a top surface of the compliant layer, and
a reflective layer covering portions of the top surface of the compliant layer,
a camera configured to generate image data from the probe assembly;
a memory storing machine-readable instructions; and
a control system including one or more processors configured to execute the machine-readable instructions to:
receive the generated image data; and
develop a topographical image of a surface of a sample based at least in part on the received image data generated by the camera.
US Pat. No. 10,988,512

METHODS OF PRODUCING AGGREGATE-FREE MONOMERIC DIPHTHERIA TOXIN FUSION PROTEINS AND THERAPEUTIC USES

The Johns Hopkins Univers...

1. A fusion protein having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 14, 15, and 43.
US Pat. No. 10,975,357

METHODS AND COMPOSITIONS RELATED TO DIFFERENTIATED LUNG CELLS

TRUSTEES OF BOSTON UNIVER...

1. A method of making induced alveolar epithelial type 2 cells (iAEC2s) which produce surfactant and are capable of self-renewal in the absence of a mesenchymal cell, the method comprising:culturing in vitro a NKX2-1+ lung epithelial progenitor cell without mesenchymal co-culture, in the simultaneous presence of:
an agonist of Wnt/beta-catenin signaling;
a corticosteroid; and
an agonist of cyclicAMP or the cyclicAMP pathway.
US Pat. No. 10,968,454

FUNCTIONALIZATION OF ENDOGENOUS BACTERIA

Massachusetts Institute o...

1. A method of functionalizing endogenous Escherichia coli (E. coli) in a subject having an inflammatory bowel disease, the method comprising:delivering to the subject having endogenous E. coli a recombinant phagemid that is engineered to contain a nucleic acid comprising an inducible promoter operably linked to a nucleotide sequence that encodes an antibody, wherein the recombinant phagemid comprises an f1 origin and a packaging site of a non-lytic filamentous bacteriophage;
thereby producing, in the subject, viable functionalized endogenous E. coli that express the antibody.

US Pat. No. 10,939,825

SYSTEMS, DEVICES, METHODS, APPARATUS AND COMPUTER-ACCESSIBLE MEDIA FOR PROVIDING OPTICAL IMAGING OF STRUCTURES AND COMPOSITIONS

The General Hospital Corp...

1. A method for determining at least one characteristic of at least one structure using a catheter, the catheter including an imaging system coupled to the catheter by a junction and controlled by a computer arrangement,the catheter comprising at least one optical fiber,
the imaging system comprising at least one electro-magnetic radiation source coupled to the at least one optical fiber, and
the computer arrangement comprising a processor,
the method comprising:
receiving, by the computer arrangement and from the imaging system via the junction, first data associated with the at least one structure;
determining, by the computer arrangement, a distance between the catheter and the at least one structure based on the first data;
receiving, by the computer arrangement and from the imaging system via the junction, second data associated with the at least one structure which is different from the first data,
wherein the first and second data are obtained from substantially the same location on or in the at least one structure, and
wherein the first data include structural information;
correcting, by the computer arrangement, a signal intensity associated with the second data based on the distance between the catheter and the at least one structure to produce corrected second data;
ascertaining, by the computer arrangement, further information associated with the at least one structure based on the corrected second data; and
determining, by the computer arrangement, the at least one characteristic of the at least one structure based on the further information.
US Pat. No. 10,927,417

GENE EXPRESSION-BASED BIOMARKER FOR THE DETECTION AND MONITORING OF BRONCHIAL PREMALIGNANT LESIONS

Trustees of Boston Univer...

1. A method of processing a sample from a subject suspected of having a premalignant bronchial lesion comprising the steps of: (a) providing a biological sample from the mouth or nose of the subject or from a brushing of the bronchi walls of the subject; and (b) measuring the expression of five or more genes in the sample by northern-blot hybridization, a ribonuclease protection assay, or a reverse transcriptase polymerase chain reaction (RT-PCR) method, wherein the five or more genes comprise ZXDC, ESR1, MYH3, RBM19, and TIMM23.

US Pat. No. 10,907,123

SUB-PASCAL UNIDIRECTIONAL FLOW VALVES

TRUSTEES OF BOSTON UNIVER...

1. A valve comprising:a body including an inner bore extending between a first port and a second port, a seat, and one or more restrainers; and
a disk including a cylindrical portion and a spherical portion, the disk being moveable between the seat and the one or more restrainers and being configured such that (i) a first pressure that is less than 1 pascal and applied in a first direction causes the disk to move from a first position towards a second position to permit fluid communication between the first port and the second port and (ii) a second pressure that is less than 1 pascal and applied in a second opposing direction causes the disk to move from the second position towards the first position to inhibit fluid communication between the first port and the second port.

US Pat. No. 10,884,089

APPARATUS FOR IMPROVING MAGNETIC RESONANCE IMAGING

Trustees of Boston Univer...

1. An apparatus for improving operation of an MRI machine characterized by a working frequency, by improving the signal-to-noise ratio of received signals, the apparatus comprising:an array of unit cells, the array sized to be disposed within a bore of the MRI machine along with a specimen in the bore, and capable of passive operation to increase signal-to-noise ratio of signals emitted by the specimen when the MRI machine is imaging the specimen, wherein:
each unit cell has a resonant frequency, and
the array has a resonance frequency at or near the working frequency, and
the unit cells configured such that they magnetically couple with one another.

US Pat. No. 10,881,789

INFUSION SYSTEM FOR PREVENTING MISCHANNELING OF MULTIPLE MEDICAMENTS

Trustees of Boston Univer...

1. A system for delivering multiple fluids to a patient, comprisingat least first and second reservoirs, wherein each of the first and second reservoirs houses a fluid and has a feature element associated therewith, wherein the feature element of the first reservoir is different than the feature element of the second reservoir,
at least first and second manifolds for completely housing the first and second reservoirs, respectively, wherein each of the manifolds has a feature element associated therewith, wherein the feature element of the first manifold is different than the feature element of the second manifold,
wherein the feature element of the first reservoir is complementary to the feature element of the first manifold and the feature element of the second reservoir is complementary to the feature element of the second manifold, such that when assembled the first reservoir is capable of only being fluidly coupled to the first manifold and the second reservoir is capable of only being fluidly coupled to the second manifold, thereby preventing mischanneling of the fluid,
wherein the first manifold includes a first outlet port and the second manifold includes a second outlet port, and wherein the first and second outlet ports are coupled to first and second inlet ports of an infusion pump; wherein the first and second manifolds are disposed on an outside of the infusion pump.

US Pat. No. 10,823,667

ENGINEERED OPTICAL FIBERS AND USES THEREOF

Trustees of Boston Univer...

1. A system for measuring a property of electromagnetic radiation, the system comprising:an electromagnetic radiation source configured to produce electromagnetic radiation;
a polarizing element configured to receive the electromagnetic radiation produced by the electromagnetic radiation source and output linearly-polarized electromagnetic radiation having a linear polarization angle ?1;
a mode converter configured to receive the linearly-polarized electromagnetic radiation and output an orbital angular momentum (OAM) mode of linearly-polarized electromagnetic radiation with a topological charge Li, the OAM mode of linearly-polarized electromagnetic radiation being a superposition of (i) a first OAM mode with topological charge Li and a first circular polarization, and (ii) a second OAM mode with topological charge Li and a second circular polarization, the first circular polarization being opposite from the second circular polarization;
an optical fiber configured to receive the first OAM mode and the second OAM mode, and support propagation to an output of the optical fiber of the first OAM mode with an effective index neff1 and the second OAM mode with an effective index neff2, an absolute difference ?neff between neff1 and neff2 being greater than or equal to 5×10?5, such that linearly-polarized electromagnetic radiation having a topological charge Li and a linear polarization angle ?2 is emitted at the output of the optical fiber; and
one or more measurement devices configured to determine the property of the electromagnetic radiation based at least on the polarization angle ?2 of the electromagnetic radiation emitted at the output of the optical fiber.

US Pat. No. 10,641,739

METHOD AND SYSTEM FOR OBLIQUE BACKSCATTERING ULTRASOUND TRANSMISSIVE CONTRAST IMAGING

Trustees of Boston Univer...

1. An oblique backscatter acoustic imaging system comprising:a transmitting transducer configured to produce focused acoustic waves propagating into and through a target;
two or more receiving transducers positioned on opposite sides of the transmitting transducer and configured to detect diffuse backscatter of the acoustic waves passing through the target; and
a signal processor configured to receive a signal from at least one of the receiving transducers representative of the detected backscatter of the acoustic waves that have passed through the target and produce a signal representative of at least one of a phase-gradient contrast signal or an absorption contrast signal from the received signal.
US Pat. No. 11,059,864

CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION

TRUSTEES OF BOSTON UNIVER...


1. A polypeptide comprising, from N-terminus to C-terminus:a) an extracellular binding domain comprising an antigen-binding fragment of an antibody;
b) a transmembrane domain;
c) a first intracellular signaling domain comprising an intracellular domain of a costimulatory molecule;
d) a repressible protease; and
e) the combination of A) an immunoreceptor tyrosine-based activation motif (ITAM) containing primary cytoplasmic signaling sequence, and B) a second intracellular signaling domain comprising an intracellular domain of a costimulatory molecule; wherein the ITAM containing primary cytoplasmic signaling sequence and the second intracellular signaling domain comprising an intracellular domain of a costimulatory molecule can be in any N-terminus to C-terminus order relative to each other.

US Pat. No. 11,047,790

METHOD AND SYSTEM FOR ENHANCED SINGLE PARTICLE REFLECTANCE IMAGING

TRUSTEES OF BOSTON UNIVER...


1. An interferometric reflectance imaging system for characterization of nanoparticles comprising:an illumination source configured to produce illumination light along an illumination path toward a target substrate;
the target substrate configured to reflect the illuminating light producing a radiation pattern along a collection path toward an imaging sensor;
wherein the collection path includes an amplitude or phase mask selected to adjust specularly reflected reference light for optimization of interferometric signal, and
wherein the target substrate includes a base substrate having a first reflecting surface and a transparent spacer layer having a first surface in contact with the first reflecting surface and a second reflecting surface on a side opposite to the first surface, and
wherein the transparent spacer layer has a predefined thickness that is determined as a function of a wavelength of the illuminating light and produces the predefined radiation pattern of optical scattering when nanoparticles are positioned on or near the second reflective surface.

US Pat. No. 11,030,531

DNA RECOMBINASE CIRCUITS FOR LOGICAL CONTROL OF GENE EXPRESSION

TRUSTEES OF BOSTON UNIVER...

1. A nucleic acid logic cassette comprising a mammalian promoter sequence operatively linked to a logic gate,wherein the logic gate comprises at least one target gene and at least two pairs of recombinase recognition sequences (RRS),
wherein each pair of RRS is recognized by a different recombinase enzyme, and wherein the RRS of each pair can be the same sequence or a different sequence recognized by the same recombinase enzyme,
wherein RRS1 is a recombinase recognition sequence (RRS) for a first recombinase enzyme (R1), RRS2 is a recombinase recognition sequence for a second recombinase enzyme (R2), RRS3 is a recombinase recognition sequence for a third recombinase enzyme (R3), RRS4 is a recombinase recognition sequence for a fourth recombinase enzyme (R4), RRS5 is a recombinase recognition sequence for a fifth recombinase enzyme (R5), RRS6 is a recombinase recognition sequence for a sixth recombinase enzyme (R6), and RRS7 is a recombinase recognition sequence for a seventh recombinase enzyme (R7),
wherein when pair of RRS for the same recombinase enzyme are in the same orientation, the intervening nucleic acid sequence between RRS pair is excised in the presence of the recombinase enzyme, and when a pair of RRS for the same recombinase are in the inverse orientation with respect to each other, the intervening nucleic acid sequence between the RRS pair is inverted in the presence of the recombinase enzyme, and
wherein the logic gate is selected from any of the following logic gates having in a 5? to 3? direction:a) a first RRS1, a first RRS2, a nucleic acid sequence encoding a target gene, a second RRS2 and a second RRS1, wherein the RRS1 and RRS2 are all in the same orientation;b) a first RRS1, a first RRS2, a stop sequence, a second RRS1, a second RRS2, and a nucleic acid sequence encoding a target gene, wherein the RRS1 and RRS2 are all in the same orientation;c) a first RRS1, a stop sequence, a second RRS1, a first RRS2, a stop sequence, a second RRS2, and a nucleic acid sequence encoding a target gene, wherein the RRS1 and RRS2 are all in the same orientation;d) a first RRS2, a first nucleic acid sequence encoding a target gene, a second RRS2, a first RRS1, and second nucleic acid sequence encoding the same target gene, a second RRS1, wherein the RRS1 and RRS2 are all in the same orientation;e) a first RRS1, a first RRS2, a first nucleic acid sequence encoding a target gene, a second RRS2, a stop sequence, a second RRS1, a second nucleic acid sequence encoding the same target gene, wherein the RRS1 and RRS2 are all in the same orientation;f) a first RRS2, a first RRS1, a first nucleic acid sequence encoding a target gene, a second RRS1, a stop sequence, a second RRS2, a second nucleic acid sequence encoding the same target gene, wherein the RRS1 and RRS2 are all in the same orientation;g) a first RRS1, a first RRS2, a stop sequence, a second RRS2, a nucleic acid encoding a target gene, a second RRS1, wherein the RRS1 and RRS2 are all in the same orientation;h) a first RRS2, a first RRS1, a stop sequence, a second RRS1, a nucleic acid encoding a target gene, a second RRS2, wherein the RRS1 and RRS2 are all in the same orientation;i) a first RRS1, a first RRS2, a nucleic acid encoding a target gene, a second RRS2, a second RRS1, wherein the RRS1 and RRS2 are all in the same orientation; andj) a first RRS1, a stop sequence, a second RRS1, a first RRS2, a stop sequence, a second RRS2, a nucleic acid encoding a target gene, wherein RR1 and RRS2 are all in the same orientation;k) a first RRS1, a first RRS2, a first nucleic acid encoding a first target gene, a second RRS2, a second nucleic acid encoding a second target gene, a second RRS1, a first RRS3, a third nucleic acid encoding a third target gene, a second RRS3, a fourth nucleic acid encoding a fourth target gene, wherein the RRS1, RRS2 and RRS3 are all in the same orientation with respect to each other;l) a first RRS1, a first RRS2, a first RRS3 in the forward orientation (RRS3for), a nucleic acid encoding a first target gene in the reverse orientation, a second RRS3 in the reverse orientation (RRS3rev), a second RRS2, a first RRS4, stop sequence, a second RRS4, a second nucleic acid sequence encoding a first target gene, a second RRS1, a first RRS5, a first RRS6, a stop sequence, a second RRS6, a third nucleic acid sequence encoding a first target gene, a second RRS5, a first RRS7 in the forward orientation (RRS7for), a forth nucleic acid sequence encoding the first target gene in the reverse orientation, a second RRS7 in the reverse orientation (RRS7rev), wherein RR1, RRS2, RRS3, RRS4, RRS5 and RRS6, are all in the same orientation with respect to each other and RRS3for and RRS3rev, and RRS7for and RRS7rev are in inverse orientation with respect to each other,m) a first RRS1, a first RRS2, a first RRS3, a first nucleic acid encoding a first target gene, a second RRS3, a second nucleic acid encoding a second target gene, a second RRS2, a first RRS4, a third nucleic acid encoding a third target gene, a second RRS4, a fourth nucleic acid encoding a fourth target gene, a second RRS1, a first RRS5, a first RRS6, a fifth nucleic acid encoding a fifth target gene, a second RRS6, a sixth nucleic acid encoding a sixth target gene, a second RRS5, a first RRS7, a seventh nucleic acid encoding a seventh target gene, a second RRS7, an eighth nucleic acid encoding an eighth target gene, wherein the RRS1, RRS2, RRS3, RRS4, RRS5, RRS6 and RRS7 are all in the same orientation with respect to each other;n) a first RRS1, a first RRS2, a first RRS3, a stop sequence, a second RRS3, a first nucleic acid encoding a first target gene, a second RRS2, a first RRS4, a second nucleic acid encoding the first target gene, a second RRS4, a third nucleic acid encoding a second target gene, a second RRS1, a first RRS5, a first RRS6, a fourth nucleic acid encoding the first target gene, a second RRS6, a fifth nucleic acid encoding the second target gene, a second RRS5, a first RRS7 a sixth nucleic acid encoding the second target gene, a second RRS7, a seventh nucleic acid encoding the first and second target gene; wherein the RRS1, RRS2, RRS3, RRS4, RRS5, RRS6 and RRS7 are all in the same orientation with respect to each other;o) a first RRS1, a second RRS2, a third RRS3, a stop sequence, a second RRS3, a first nucleic acid encoding a first target gene, a second RRS2, a first RRS4, a second nucleic acid encoding the first target gene and a second target gene, a second RRS4, a stop sequence, a second RRS1, a first RRS5, a first RRS6, a third nucleic acid encoding the first and the second target gene, a second RRS6, a fourth nucleic acid encoding the second target gene, a second RRS5, a first RRS7, a stop sequence, a second RRS7, a fifth nucleic acid encoding the first and second target gene, wherein the RRS1, RRS2, RRS3, RRS4, RRS5, RRS6 and RRS7 are all in the same orientation with respect to each other;p) a first RRS1, a second RRS2, a third RRS3, a stop sequence, a second RRS3, a first nucleic acid encoding a first target gene, a second RRS2, a first RRS4, a second nucleic acid encoding the first target gene, a second RRS4, a third nucleic acid encoding a second target gene, a second RRS1, a first RRS5, a first RRS6, a stop sequence, a second RRS6, a fourth nucleic acid encoding the first and second target gene, a second RRS5, a first RRS7, a fifth nucleic acid encoding the first target gene, a second RRS7, a stop sequence; wherein the RRS1, RRS2, RRS3, RRS4, RRS5, RRS6 and RRS7 are all in the same orientation with respect to each other;q) a first RRS1, a first RRS2, a first RRS3, a stop sequence, a second RRS3, a first nucleic acid encoding a first target gene, a second RRS2, a first RRS4, a stop sequence, a second RRS4, a second nucleic acid encoding the first target gene, a second RRS1, a first RRS5, a first RRS6, a stop sequence, a second RRS6, a third nucleic acid encoding the first target gene, a second RRS5, a first RRS7, a stop sequence, a second RRS7, a fourth nucleic acid encoding the first target gene, wherein the RRS1, RRS2, RRS3, RRS4, RRS5, RRS6 and RRS7 are all in the same orientation with respect to each other;s) a first RRS1, a first RRS2, a stop sequence, a second RRS2, a first nucleic acid encoding a first target gene, a second RRS1, a first RRS3, a second nucleic acid encoding a second target gene, a second RRS3, a third nucleic acid encoding a third target gene, wherein the RRS1, RRS2 and RRS3 are all in the same orientation with respect to each other;t) a half adder comprising 3 constructs, comprising:i. a first construct comprising in a 5? to 3? direction: a first RRS1, a second RRS2, a stop sequence, a second RRS2, a first nucleic acid encoding a first target gene, a second RRS1;
ii. a second construct comprising in a 5? to 3? direction: a first RRS2, a second RRS1, a stop sequence, a second RRS1, a first nucleic acid encoding the first target gene, a second RRS2;
iii. a third construct comprising in a 5? to 3? direction: a first RRS1, a stop sequence, a second RRS1, a first RRS2, a stop sequence, a second RRS2, a first nucleic acid encoding a second target gene;
wherein the RRS1, RRS2 and RRS3 are all in the same orientation with respect to each other;u) a half adder comprising 2 constructs, comprising:i. a first construct comprising in a 5? to 3? direction; a first RRS1, a first RRS3, a stop sequence, a second RRS3, a first nucleic acid encoding a first target gene, a second RRS1, a first RRS2, a second nucleic acid sequence encoding the first target gene, and a second RRS2, and
ii. a second construct comprising in a 5? to 3? direction; a first RRS1, a stop sequence, a second RRS1, a first RRS2, a stop sequence, a second RRS2, a first nucleic acid encoding a second target gene,
wherein the RRS1, RRS2 and RRS3 are all in the same orientation with respect to each other;v) a first RRS1, a first RRS3, a stop sequence, a second RRS3, a first nucleic acid encoding a first target gene, a second RRS1, a first RRS2, a second nucleic acid encoding the first target gene, a second RRS2, a third nucleic acid encoding a second target gene, wherein the RRS1, RRS2 and RRS3 are all in the same orientation with respect to each other.

US Pat. No. 10,990,626

DATA STORAGE AND RETRIEVAL SYSTEM USING ONLINE SUPERVISED HASHING

Trustees of Boston Univer...

1. A data storage and retrieval system, comprising:a storage subsystem for storing a dataset of content items, at least some of the content items of the dataset being labelled content items having respective labels describing respective aspects of the content items; and
a processing subsystem coupled to the storage subsystem and having a communications interface coupled to receive additions to the dataset and queries of the dataset, the processing subsystem being configured and operative to:
maintain an index of the content items using hash codes and predetermined codewords as index values, the hash codes being dynamically generated by an online-learned hash-based mapping, the codewords representing respective labels of the labelled content items of the dataset, the codewords being error-correcting codes protecting against errors in the hash-based mapping and promoting selectivity of the hash codes produced by the hash-based mapping;
maintain and dynamically update the hash-based mapping, and use the hash-based mapping to generate the hash codes as content items of the dataset are indexed, the hash-based mapping preserving semantic similarities of content items, the hash-based mapping being updated using an objective function of distance between the hash codes produced by the hash-based mapping and respective codewords for the labelled content items; and
search the index to retrieve stored content items in response to the queries received via the communications interface, including (i) using the hash-based mapping to calculate a query hash code from a content item of the query, and (ii) using the query hash code to retrieve stored content items indexed by similar codewords or hash codes;
wherein the processing subsystem performs a randomized reservoir sampling method that (i) maintains a reservoir sampling set of randomly selected content items and associated labels as they are added to the dataset during operation, (ii) uses the reservoir sampling set to determine when to update the index, and (iii) updates the index at determined times.

US Pat. No. 10,984,130

EFFICIENTLY QUERYING DATABASES WHILE PROVIDING DIFFERENTIAL PRIVACY

Georgetown University, W...

1. A system comprising:a plurality of oblivious random-access memories (ORAMs), wherein the plurality of ORAMs are executing on multiple servers; and
a database query server, wherein the query server is configured to communicate with the plurality of ORAMs via a computer network and performs operations, the operations comprising:
storing separate database record subsets of a set of database records in the plurality of ORAMs,
receiving a database query from a client,
determining a number of the database records to be retrieved from the plurality of ORAMs that satisfies a differential privacy constraint,
using the plurality of ORAMs to concurrently retrieve the determined number of database records from the separate database record subsets stored in the plurality of ORAMs, wherein the retrieved database records comprises one or more database records that match the received query and an additional one or more database records, and
returning the one or more database records that match the received query to the client.

US Pat. No. 10,981,850

ONE-STEP FLOW-MEDIATED SYNTHESIS OF CANNABIDIOL (CBD) AND DERIVATIVES

TRUSTEES OF BOSTON UNIVER...

1. A process for the preparation of a cannabidiol (CBD) or a derivative thereof, the process comprising:(a) providing a solution comprising of a first compound that is a 1,3-diene, an allylic alcohol or an allylic ether and a second compound of Formula (IIA) or (IIB) into a packed-bed reactor (PBR) comprising a solid or heterogeneous catalyst;
(b) circulating the first and second compound through the PBR to react the first compound with the second compound;
(c) collecting from the PBR a solution comprising the CBD or a derivative thereof;
wherein the structures of (IIA) and (IIB) are:

wherein: Z1 is CR2 or N;
Z2 is CR4 or N;
wherein R1, R3, R5, are each independently selected from the group consisting of H, OH, —CO2H, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, heterocycle, —X2RK, or halides,
wherein R2, and R4, are each independently selected from the group consisting of H, OH, —CO2H, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, heterocycle, —X2RK and not selected from halides,
wherein the alkyl, alkenyl, alkynyl or acyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, O-alkyl, —NRARB, —S-alkyl, —SO-alkyl, —SO2-alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocycle; and the alkenyl, alkynyl, or acyl group optionally includes —O—, —S—, —SO2—, —N(RG)— substituting one or more carbons in the carbon chain,
wherein the aryl or heteroaryl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, OH, alkyl, O-alkyl, —COOH, —C(O)—C1-4 alkyl, —C(O)O—C1-4 alkyl, —NRCRD, —S-alkyl, —SO-alkyl and —SO2-alkyl;
wherein X1 is selected from —O—, —S—, —SO2—, —N(RE)—;
wherein X2 is selected from —O—, —S—, —SO2—, —N(RF)—;
wherein RA, RB, RC, RD, RE, RF, RK RG are each independently selected from hydrogen and C1-4 alkyl;
or a pharmaceutically acceptable salt or ester thereof.

US Pat. No. 10,953,107

POLYPEPTIDE COMPOSITIONS AND METHODS FOR SITE-SPECIFIC TARGETING OF THERAPEUTIC AGENTS

Trustees of Boston Univer...

1. A composition comprising:a. a first polypeptide component comprising a V/K-type docking peptide comprising:
the sequence (XJJXJJJ)z where each X is independently a hydrophobic amino acid, each J is independently any amino acid, z is an integer greater than or equal to 1, and the 7th position of XJJXJJJ is a valine;
b. a second polypeptide component comprising a V/K-type docking peptide comprising:
the sequence (XJJXJJJ)z where each X is independently a hydrophobic amino acid, each J is independently any amino acid, z is an integer greater than or equal to 1, and the 7th position of XJJXJJJ is a valine;
c. a third polypeptide component comprising a V/E-type docking peptide comprising:
the sequence (XJJXJJJ)z where each X is independently a hydrophobic amino acid, each J is independently any amino acid, z is an integer greater than or equal to 1, and the 5th position of XJJXJJJ is a valine; and
d. a fourth polypeptide component comprising a V/E-type docking peptide comprising:
the sequence (XJJXJJJ)z where each X is independently a hydrophobic amino acid, each J is independently any amino acid, z is an integer greater than or equal to 1, and the 5th position of XJJXJJJ is a valine;
wherein the z of at least one docking peptide is an integer greater than or equal to 3.

US Pat. No. 10,947,876

AIR-TRANSPARENT SELECTIVE SOUND SILENCER USING ULTRA-OPEN METAMATERIAL

TRUSTEES OF BOSTON UNIVER...

1. An apparatus comprising:a first channel having a first inlet and a first outlet, the first channel open to propagation of a first wave at a target frequency therethrough and having a first area in cross-section, and
one or more second channels each open to the propagation of a second wave at the target frequency therethrough, and each having a second inlet and a second outlet, the one or more second channels defining a second area in cross-section,
wherein each of the one or more second channels is disposed relative to the first channel such that the second wave at the target frequency exiting the one or more second outlets is capable of destructively interfering with the first wave at the target frequency exiting the first channel, and
wherein the first area in cross-section is larger than the second area in cross-section such that the apparatus has an openness ratio of at least 0.8.

US Pat. No. 10,913,970

METHOD AND DEVICE FOR ANTIBIOTIC SUSCEPTIBILITY TESTING BASED ON FLUCTUATIONS OF ELECTRICAL RESISTANCE IN A MICROCHANNEL

TRUSTEES OF BOSTON UNIVER...

1. A system for antibiotic susceptibility testing comprising:a) a microchannel extending from a first end to second end;
b) at least one reservoir connected to the microchannel;
c) voltage source connected to the first end and the second end of the microchannel to produce a substantially constant electric potential and induce a current to flow through the microchannel; and
d) a signal measuring device for measuring changes in current through the microchannel over time.

US Pat. No. 10,866,230

FIBER COATED NANOPORES

TRUSTEES OF BOSTON UNIVER...

1. An article comprising: (i) a substrate having a first surface and a second surface; (ii) at least one nanopore extending through the substrate, thus forming a channel connecting from the first surface to the second surface of the substrate, wherein the nanopore has a first opening that opens to the first surface of the substrate and a second opening that opens to the second surface of the substrate; and (iii) a 3D porous coating on at least one of the first or second surface of the substrate, wherein the porous coating comprises oligomer or polymer nanofibers, and wherein the nanopore has a diameter of about 2 nm to about 50 nm, and wherein the 3D porous coating covers at least one of the first opening or the second opening of said at least one nanopore, wherein the oligomer or polymer is a linear, comb, branched, or dendritic oligomer or polymer represented by one of the following formulas:
wherein:
Q is independently selected from among O, S, Se, or NH;
G? is each independently selected from among the following structures:

R is selected from among a hydrogen, straight or branched alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl or arylalkyl chain of 1-50 carbons, wherein each alkyl, cycloalkyl, aryl, olefin, silyl, alkylsilyl, arylsilyl, alkylaryl, fluorocarbon, or arylalkyl chain is optionally substituted internally or terminally by one or more hydroxyl, hydroxyether, carboxyl, carboxyester, carboxyamide, amino, mono- or di-substituted amino, thiol, thioester, sulfate, phosphate, phosphonate, or halogen substituents; or
R is selected from among poly(ethylene glycol), poly(ethylene oxide), poly(hydroxyacid)), a carbohydrate, a protein, a polypeptide, an amino acid, a nucleic acid, a nucleotide, a polynucleotide, any DNA or RNA segment, a lipid, a polysaccharide, an antibody, a pharmaceutical agent, or any epitope for a biological receptor; or
R is selected from among a photocrosslinkable or ionically crosslinkable group;
n is independently selected from an integer of 1-1000;
each polymeric terminal group is selected from among amines, thiols, amides, phosphates, sulphates, hydroxides, metals, alkanes, alkenes and alkynes.

US Pat. No. 10,857,287

INFUSION SYSTEM AND COMPONENTS THEREOF

Trustees of Boston Univer...

1. A medicament infusion system for delivering multiple medicaments to a patient, the medicament infusion system comprising:a first reservoir set comprising:
a first inlet connector configured to engage a first medicament reservoir that comprises a first medicament reservoir port and a first medicament, the first inlet connector being configured to fit over at least a portion of the first medicament reservoir port, the first inlet connector comprising:
a first needle configured to receive the first medicament;
a first engaging member configured to engage a portion of the first medicament reservoir thereby coupling the first inlet connector to the first medicament reservoir; and
a first check valve configured to allow the first medicament to flow from the first medicament reservoir in response to a first threshold fluid pressure being applied to the first medicament;
wherein the first threshold fluid pressure is greater than a gravitationally induced hydrostatic pressure caused by placing the first reservoir set above an infusion site of the patient; and
a second reservoir set comprising:
a second inlet connector configured to engage a second medicament reservoir that comprises a second medicament reservoir port and a second medicament, the second inlet connector being configured to fit over at least a portion of the second medicament reservoir port, the second inlet connector comprising:
a second needle configured to receive the second medicament; and
a second engaging member configured to engage a portion of the second medicament reservoir thereby coupling the second inlet connector to the second medicament reservoir.

US Pat. No. 10,827,911

OPTICAL IMAGING SYSTEM EMPLOYING VORTEX FIBER FOR MULTIPLE-MODE ILLUMINATION

Trustees of Boston Univer...

1. A vortex optical fiber for use in an illumination subsystem of an optical imaging system, the vortex optical fiber comprising an elongated optically transmissive medium having a set of regions including a core region, a trench region surrounding the core region, a ring region surrounding the trench region, and a cladding region, the set of regions having a doping profile providing a ?neff for vector modes in an LP11 mode group of greater than 1×10?4 in the visible spectral range so as to simultaneously guide stable Gaussian and orbital angular momentum (OAM) carrying modes at corresponding visible wavelengths.